<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        5-597-09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRETERAX ARGININE 2.5MG-0.625MG F.C. TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PERINDOPRIL ARGININE,INDAPAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5,0.625
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        38.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SERVIER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SERVIER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09BA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Preterax 2.5mg/0.625mg is a combination of two active ingredients, perindopril and indapamide. It is an anti-hypertensive and is used in the treatment of high blood pressure (hypertension) in adults.</p><p><strong>&nbsp;</strong></p><p>Perindopril belongs to a class of medicines called ACE inhibitors. These work by widening the blood vessels, which makes it easier for your heart to pump blood through them. Indapamide is a diuretic. Diuretics increase the amount of urine produced by the kidneys. However, indapamide is different from other diuretics, as it only causes a slight increase in the amount of urine produced. Each of the active ingredients reduces blood pressure and they work together to control your blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Preterax </strong><strong>2.5mg/0.625mg:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to perindopril or any other ACE inhibitor, or to indapamide or any other sulphonamides or any of the other ingredients of this medicine (listed in section 6) ,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have experienced symptoms such as wheezing, swelling of the face or tongue, intense itching or severe skin rashes with previous ACE inhibitor treatment or if you or a member of your family have had these symptoms in any other circumstances (a condition called angioedema),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease or suffer from a condition called hepatic encephalopathy (degenerative disease of the brain),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe kidney disease &nbsp;where the blood supply to your kidneys is reduced (renal artery stenosis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;if you are receiving dialysis, or any other type of blood filtration. Depending on the machine that is used, Preterax may not be suitable for you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low blood potassium,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are suspected of having untreated decompensated heart failure (severe water retention, difficulty in breathing),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant (It is also better to avoid Preterax 2.5mg/0.625mg in early pregnancy - see &ldquo;Pregnancy section),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have taken or are currently taking sacubitril/valsartan, a medicine for heart failure, as the risk of angioedema (rapid swelling under the skin in an area such as the throat) is increased (see &ldquo;Warning and Precaution&rdquo; and &ldquo;Other medicines and &ldquo;Other medicines and Preterax 2.5mg/0.625mg&rdquo;).</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p>&nbsp;Talk to your doctor or pharmacist before taking Preterax 2.5mg/0.625mg:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have aortic stenosis (narrowing of the main blood vessel leading from the heart) or hypertrophic cardiomyopathy (heart muscle disease) or renal artery stenosis (narrowing of the artery supplying the kidney with blood),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart failure or any other heart problems,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems, or if you are receiving dialysis,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a decrease in vision or eye pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking Preterax 2.5mg/0.625mg. This can lead to permanent vision loss, if not treated. If you earlier have had a penicillin or sulfonamide allergy, you can be at higher risk of developing this,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have muscle disorders including muscle pain, tenderness, weakness or cramps,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have abnormally increased levels of a hormone called aldosterone in your blood (primary aldosteronism),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a collagen disease (skin disease) such as systemic lupus erythematosus or scleroderma,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have atherosclerosis (hardening of the arteries),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from hyperparathyroidism (overactive parathyroid gland),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from gout,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are on a salt restricted diet or use salt substitutes which contain potassium,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take lithium or potassium-sparing drugs (spironolactone, triamterene) or potassium supplements as their use with Preterax 2.5mg/0.625mg should be avoided (see &ldquo;Taking other medicines&rdquo;),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are elderly,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had photosensitivity reactions,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe allergic reaction with swelling of the face, lips, mouth , tongue or throat which may cause difficulty in swallowing or breathing (angioedema). This may occur at any time during treatment. If you develop such symptoms, you should stop taking the treatment and see a doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an &ldquo;angiotensin II receptor blocker&rdquo; (ARBs) (also known as sartans - for example valsartan, telmisartan, irbesartan), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Preterax 2.5mg/0.625mg&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are of black origin since you may have a higher risk of angioedema and this medicin may be less effective in lowering your blood pressure than in non-black patients,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a haemodialysis patient dialysed with high-flux membranes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines, the risk of angioedema is increased:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; racecadotril (used to treat diarrhoea),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors (used to avoid rejection of transplanted organs and for cancer),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sacubitril (available as fixed-dose combination with valsartan), used to treat long-term heart failure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; linagliptin, saxagliptin, sitagliptin, vildagliptin and other drugs belonging to the class of the also called gliptins (used to treat diabetes).</p><p>&nbsp;</p><p><u>Angioedema</u></p><p>Angioedema (a severe allergic reaction with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing) has been reported in patients treated with ACE inhibitors, including Preterax. This may occur at any time during treatment. If you develop such symptoms, you should stop taking Preterax and see a doctor immediately. See also section 4.</p><p>&nbsp;</p><p>You must tell your doctor if you think that you are (<u>or might become</u>) pregnant. Preterax 2.5mg/0.625mg is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p>&nbsp;</p><p>When you are taking Preterax 2.5mg/0.625mg, you should also inform your doctor or the medical staff:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are to undergo anaesthesia and/or surgery,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recently suffered from diarrhoea or vomiting, or are dehydrated,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are to undergo dialysis or LDL apheresis (which is removal of cholesterol from your blood by a machine),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are going to have desensitisation treatment to reduce the effects of an allergy to bee or wasp stings,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are to undergo a medical test that requires injection of an iodinated contrast agent (a substance that makes organs like kidney or stomach visible on an X-ray),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have changes in your vision or pain in one or both of your eyes while taking Preterax. This could be a sign that you are developing glaucoma, increased pressure in your eye(s). You should discontinue Preterax treatment and seek medical attention.</p><p>&nbsp;</p><p>Athletes should be aware that Preterax 2.5mg/0.625mg contains an active ingredient (indapamide) which may give a positive reaction in drug tests.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Preterax 2.5mg/0.625mg should not be given to children and adolescents.</p><p>&nbsp;</p><p><strong>Other medicines and Preterax</strong><strong> 2.5mg/0.625mg </strong></p><p>&nbsp;Tell your doctor or pharmacist if you are taking,&nbsp; have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>You should avoid Preterax 2.5mg/0.625mg with:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium (used to treat mania or depression),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren (medicine used to treat hypertension) if you have no diabetes mellitus or kidney problems,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium-sparing diuretics ( e.g. triamterene, amiloride), potassium salts, other drugs which can &nbsp;increase potassium in your body (such as heparin, a medicine used to thin blood to prevent clots; trimethoprim and co-trimoxazole also known as trimethoprim/sulfamethoxazole for infections caused by bacteria),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; estramustine (used in cancer therapy),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines used to treat high blood pressure: angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers.</p><p>&nbsp;</p><p>Treatment with Preterax 2.5mg/0.625mg can be affected by other medicines. Your doctor may need to change your dose and/or to take other precautions. Make sure to tell your doctor if you are taking any of the following medicines as special care may be required:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines for treating high blood pressure, including angiotensin II receptor blocker (ARB) or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;aliskiren (see also information under the headings &ldquo;Do not take Preterax 2.5mg/0.625mg&rdquo; and &ldquo;Take &nbsp;&nbsp;&nbsp;&nbsp;special care with Preterax 2.5mg/0.625mg&rdquo;) or diuretics (medicines which increase the amount of &nbsp;&nbsp;urine produced by the kidneys),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium-sparing drugs used in the treatment of heart failure: eplerenone and spironolactone at doses &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;between 12.5 mg to 50 mg per day,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines, which are most often used to treat diarrhoea (racecadotril) or avoid rejection of transplanted organs (sirolimus, everolimus, temsirolimus and other drugs belonging to the class of so-called mTor inhibitors). See section &ldquo;Warnings and precautions&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sacubitril/valsartan (used to treat long-term heart failure). See sections &ldquo;Do not take Preterax 2.5mg/0.625mg&rdquo; and &ldquo;Warnings and precautions&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaesthetic medicines,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; iodinated contrast agent,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics used to treat bacterial infections (e.g moxifloxacin, sparfloxacin, erythromycin by injection)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methadone (used to treat addiction),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; procainamide (for the treatment of an irregular heart beat),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allopurinol (for the treatment of gout),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mizolastine, terfenadine or astemizole (antihistamines for hay fever or allergies),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antihistamines used to treat allergic reactions, such as hay fever (e.g mizolastine, terfenadine, astemizole),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids used to treat various conditions including severe asthma and rheumatoid arthritis,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; immunosuppressants used for the treatment of auto-immune disorders or following transplant surgery to prevent rejection (e.g. ciclosporin, tacrolimus),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; halofantrine (used to treat certain types of malaria),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pentamidine (used to treat pneumonia),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injectable gold (used to treat rheumatoid polyarthritis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vincamine (used to treat symptomatic cognitive disorders in elderly including memory loss),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bepridil (used to treat angina pectoris),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used for heart rhythm problems (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, digitalis, bretylium),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cisapride, diphemanil (used to treat gastric and digestive problems),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin or other cardiac glycosides (for the treatment of heart problems),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baclofen (to treat muscle stiffness occurring in diseases such as multiple sclerosis),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to treat diabetes such as insulin, metformin or gliptins,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium including calcium supplements,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stimulant laxatives (e.g. senna),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatory drugs (e.g. ibuprofen) or high dose salicylates (e.g. acetylsalicylic acid ( a substance presents in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting )),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amphotericin B by injection (to treat severe fungal disease),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat mental disorders such as depression, anxiety, schizophrenia&hellip;(e.g. tricyclic antidepressants, neuroleptics (such as amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol)),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tetracosactide (to treat Crohn&rsquo;s disease),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trimethoprim (for the treatment of infections),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vasodilators including nitrates (products that make the blood vessels become wider),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used for the treatment of low blood pressure, shock or asthma (e.g. ephedrine, noradrenaline or adrenaline).</p><p>&nbsp;</p><p><strong>Preterax</strong><strong> </strong><strong>2.5mg/0.625mg</strong> <strong>with food and drink</strong></p><p>It is preferable to take Preterax 2.5mg/0.625mg before a meal.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>You must tell your doctor if you think that you are (<u>or might become</u>) pregnant.</p><p>Your doctor will normally advise you to stop taking Preterax 2.5mg/0.625mg before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Preterax 2.5mg/0.625mg. Preterax 2.5mg/0.625mg is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Preterax 2.5mg/0.625mg is not recommended if you are breast-feeding.</p><p>Tell your doctor immediately if you are breast-feeding or about to start breast-feeding.</p><p>See your doctor immediately.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Preterax 2.5mg/0.625mg usually does not affect alertness but different reactions such as dizziness or weakness in relation to the decrease in blood pressure may occur in certain patients. If affected, your ability to drive or to operate machinery may be impaired.</p><p>&nbsp;</p><p><strong>Preterax 2.5mg/0.625mg contains lactose monohydrate.</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Preterax 2.5mg/0.625mg contains sodium</strong></p><p>Preterax 2.5mg/0.625mg contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine&nbsp; exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended&nbsp; dose is one tablet once a day. Your doctor may decide to increase the dose to 2 tablets daily or to modify the dosage regimen if you suffer from renal impairment. Take your tablet preferably in the morning and before a meal. Swallow the tablet with a glass of water.</p><p>&nbsp;</p><p>The score line is not intended for breaking the tablet.</p><p>&nbsp;</p><p><strong>If you take more Preterax </strong><strong>2.5mg/0.625mg</strong><strong> </strong><strong>than you should</strong></p><p>If you take too many tablets, contact your doctor or nearest hospital casualty department immediately. The most likely effect in case of overdose is low blood pressure. If marked low blood pressure occurs (associated with nausea, vomiting, cramps, dizziness, sleepiness, mental confusion, changes in the amount of urine produced by kidneys), lying down with the legs raised can help.</p><p>&nbsp;</p><p><strong>If you forget to take Preterax </strong><strong>2.5mg/0.625mg</strong></p><p>It is important to take your medicine every day as regular treatment is more effective. However, If you forget to take a dose of Preterax 2.5mg/0.625mg, take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Preterax </strong><strong>2.5mg/0.625mg</strong></p><p>As the treatment for high blood pressure is usually life-long, you should discuss with your doctor before stopping this medicinal product.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine , ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine &nbsp;can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Stop taking the medicinal product and see a doctor immediately, </strong><strong>if you experience any of the following side effects</strong><strong> that can be serious</strong>:</p><p>- Severe dizziness or fainting due to low blood pressure (Common - may affect up to 1 in 10 people),</p><p>- Bronchospasm (tightening of the chest, wheezing and shortness of breath (Uncommon) (may affect up to 1 in 100 people),</p><p>- Swelling of the face, lips, mouth, tongue or throat, difficulty in breathing (angioedema) (See section 2 &ldquo;Warning and precaution&rdquo;) (Uncommon) (may affect up to 1 in 100 people),</p><p>- Severe skin reactions including erythema multiforme (a skin rash which often starts with red itchy patches on your face, arms or legs) or intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome) or other allergic reactions (Very rare) (may affect up to 1 in 10,000 people),</p><p>- Cardiovascular disorders (irregular heart beat, angina pectoris (pains to the chest, jaw and back, brought on by physical effort), heart attack) (Very rare) (may affect up to 1 in 10,000 people),</p><p>- Weakness of arms or legs, or problems speaking which could be a sign of a possible stroke (Very rare) (may affect up to 1 in 10,000 people),</p><p>- Inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell (Very rare) (may affect up to 1 in 10,000 people),</p><p>- Yellowing of the skin or eyes (jaundice) which could be a sign of hepatitis (Very Rare) (may affect up to 1 in 10,000 people),</p><p>- Life-threatening irregular beat.(Not known),</p><p>- Disease of the brain caused by liver illness (Hepatic encephalopathy) (Not known), Muscle weakness, cramps, tenderness or pain and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown (Not known).</p><p>&nbsp;</p><p>In decreasing order of frequency, side effects can include:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (may affect up to 1 in 10 people):</p><p>Low potassium in the blood, skin reactions in subjects predisposed to allergic and asthmatic reactions , headache, dizziness, vertigo, pins and needles, vision disturbances, tinnitus (sensation of noises in the ears), cough, shortness of breath (dyspnoea), gastro-intestinal disorders (nausea, vomiting, abdominal pain, taste disturbances, dyspepsia or difficulty of digestion, diarrhoea, constipation), allergic reactions (such as skin rashes, itching), cramps, feeling of tiredness,</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (may affect up to 1 in 100 people):</p><p>Mood swings, depression, sleep disturbances, , urticaria, purpura (red pinpoints on skin), blister cluster, kidney problems, impotence (inability to obtain or maintain an erection), sweating, an excess of eosinophils (a type of white blood cells), change in laboratory parameters: high blood level of potassium reversible on discontinuation, low blood level of sodium that may lead to dehydration and low blood pressure,, somnolence, fainting, palpitations (awareness of your heartbeat), tachycardia (fast heartbeat), hypoglycaemia (very low blood sugar level) in case of diabetic patients, vasculitis (inflammation of blood vessels), dry mouth, photosensitivity reactions (increased sensitivity of the skin to sun), arthralgia (joint pain), myalgia (muscle pain), chest pain, malaise, oedema peripheral, fever, increased blood urea, increased blood creatinine, fall.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (may affect up to 1 in 1000 people):</p><p>Psoriasis worsening, changes in laboratory parameters: low chloride in the blood, low magnesium in the blood, increased level of liver enzymes, high level of serum bilirubin, fatigue, flushing, decrease or absence urine output, acute renal failure.</p><p>Dark urine, feeling sick (nausea) or being sick (vomiting), muscle cramps, confusion and seizures. These may be symptoms of a condition called SIADH (inappropriate antidiuretic hormone secretion).</p><p>&nbsp;</p><p>.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare (may affect up to 1 in 10,000 people):</p><p>Confusion,&nbsp; eosinophilic pneumonia (a rare type of pneumonia), rhinitis (blocked up or runny nose), severe kidney problems, changes in blood values such as a lower number of white and red blood cells, lower haemoglobin, lower number of blood platelets, high level of calcium in the blood, abnormal hepatic function.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known (frequency cannot be estimated from the available data): Abnormal ECG heart tracing, changes in laboratory parameters: high uric acid levels and high sugar levels in the blood, short sightedness (myopia), vision blurred, visual impairment, , &nbsp;decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma), discoloration, numbness and pain in fingers or toes (Raynaud&rsquo;s phenomenon). If you suffer from systemic lupus erythematosus (a type of collagen disease), this might get worse.</p><p>&nbsp;</p><p>Disorders of the blood, kidney, liver or pancreas and changes in laboratory parameters (blood tests) can occur. Your doctor may need to give you blood tests to monitor your condition.</p><p>&nbsp;</p><p>If you have these symptoms contact your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p><p>You can also report side effects directly via the national reporting system.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight&nbsp; and reach&nbsp; of children.</p><p>&nbsp;</p><p>Do not use this medicine &nbsp;after the expiry date which is stated on the carton and container. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Keep the container tightly closed in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines&nbsp; via wastewater or household waste. Ask your pharmacist how to throw away&nbsp; medicines you no longer use . These measures will help&nbsp; protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are perindopril arginine and indapamide. One film-coated tablet contains 2.5 mg perindopril arginine (corresponding to 1.6975 mg perindopril) and 0.625mg indapamide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients in the tablet core<em> </em>are: lactose monohydrate, magnesium stearate (E470B), maltodextrin, anhydrous colloidal silica (E551), sodium starch glycolate (type A), and in the tablet film-coating: glycerol (E422), hypromellose (E464), macrogol 6000, magnesium stearate (E470B), titanium dioxide (E171).</p><p><!--[if !supportLists]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Preterax 2.5mg/0.625mg tablets are white, rod-shaped film-coated tablets with an embossed line on both faces. One film-coated tablet contains 2.5 mg perindopril arginine and 0.625 mg indapamide.
	The tablets are available in containers of 14, 20, 28, 30, 50, 56, 60, 90, 100 or 500 tablets.
	Not all pack sizes may be available.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong>:</p><p>Les Laboratoires Servier</p><p>50, rue Carnot</p><p>92284 Suresnes cedex - France</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Servier (Ireland) Industries Ltd</p><p>Gorey Road</p><p>Arklow - Co. Wicklow &ndash; Ireland</p><p>&nbsp;</p><p><strong>Packed by</strong></p><p>AJA Pharmaceutical Industries Company Ltd</p><p>Building No. 6979, Hail Industrial City, Hail 55414</p><p>Saudi Arabia</p><p>Tel.: +966 11 268 7900</p><p>Fax: +966 11 268 7911</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>Saudi Arabia</strong></p><p>Servier Saudi Arabia Scientific Office</p><p>3533 Al Hawiy&nbsp;- Hitteen Dist.</p><p>1st floor - Office #101</p><p>Kingdom of Saudi Arabia</p><p>Tel.: +966 011 252 2330</p><p>E-mail: regulatory.sa1@servier.com</p></td><td style="vertical-align:top"><p><strong>Gulf Countries</strong></p><p>Les Laboratoires Servier Scientific Office</p><p>P.O. Box 1586, Level 15, Arenco Tower, Dubai Media city, Sheikh Zayed Road,</p><p>Dubai, UAE</p><p>Tel: +971 4 3329903</p><p>E-mail: magdy.abdou@servier.com</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2022

e. To report any side effect(s):

•	Saudi Arabia:

- National Pharmacovigilance Center (NPC)
- SFDA call Center 19999
- E-mail: npc.drug@sfda.gov.sa
- Website: https://ade.sfda.gov.sa/

•	Other GCC states:

- Please contact the relevant competent authority.

f. Council of Arab Health Ministers:


This is a Medicament

- Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
- Follow the doctor's prescription, the method of use and the instruction of the pharmacist who sold the medicament.
- The doctor and the pharmacist are the experts in medicines, their benefits and risks.
- Do not by yourselves interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.
- Keep all medicaments out of reach of children

Council of Arab Health Ministers
		                       Union of Arab Pharmacists

g. This patient information leaflet is approved by the Saudi Food and Drug Authority 


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة هو دواء يجمع بين مادتين فعّالتين: البيريندوبريل والإنداباميد. وهو مضاد لارتفاع ضغط الدم، ويوصف لعلاج ضغط الدم المرتفع لدى البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي البيريندوبريل إلى مجموعة مثبطات الإنزيم المحوّل للأنجيوتنسين. وهو يعمل على توسيع الأوعية الدموية، مما يسهّل عمل القلب في ضخّ الدم في الأوعية الدموية. أما الإنداباميد فهو مدّر للبول. تسبب المدرّات زيادة كمية البول الذي تنتجه الكليتان. ولكن الإنداباميد يختلف عن المدرّات الأخرى بأنه يزيد كمية البول بشكل ضئيل. تعمل هاتان المادتان الفعالتان على تخفيض الضغط الشرياني وتشتركان معًا في التحكم به.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إذا كان طبيبك قد سبق وأعلمك بأنك مصاب بعدم تحمّل بعض أنواع السكاكر ، فاتصل بالطبيب قبل المباشرة بتناول هذا المستحضر الدوائي.</p><p dir="RTL">لا تتناول أبدًا بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه مادة البيريندوبريل أو تجاه أي مادة أخرى من مثبطات الإنزيم المحوّل للأنجيوتنسين، أو تجاه الإنداباميد، أو أي من مركبات السلفوناميد الأخرى، أو تجاه أية مادة أخرى من مكونات هذا الدواء المذكورة في القسم ٦،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت في السابق من أعراض كالصفير في التنفّس، أو من تورّم في الوجه أو اللّسان، أو من حكة أو طفح جلدي شديد بسبب &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;علاج سابق بالأدوية المثبطة للإنزيم المحوّل للأنجيوتنسين، أو إذا كنت قد أصبت أو أي من أفراد أسرتك في أي ظرف من الظروف بهذه الأعراض (الحالة التي تدعى الوذمة الوعائيّة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بالسكّري أو باضطراب الوظيفة الكلوية وتتلقى علاجا يحتوي على أليسكيرين من أجل خفض ضغطك الشرياني،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي شديد أو من الاعتلال الدماغي الكبدي (اضطراب عصبي يحدث أثناء مرض الكبد)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل كلوية مع تناقص ورود الدم إلى الكليتين (تضيّق الشريان الكلوي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تخضع للديلزة أو أي نوع آخر من عمليات تنقية الدم. قد يكون بريتيراكس غير مناسب لك اعتمادا على الألة المستخدمة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت معدّلات البوتاسيوم في دمك منخفضة &nbsp;بشكل غير طبيعي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند الشك بوجود حالة غير معالجة من قصور القلب غير المعاوض (وجود احتباس مائي شديد وصعوبة في التنفس(،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا لأكثر من ثلاثة أشهر (كما يفضّل تجنب تناول بريتيراكس في المراحل المبكرة من الحمل &ndash; راجعي قسم &quot;الحمل &quot;)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت أو تتلقى علاجا بـ ساكوبتريل/فالسارتان، وهو دواء لعلاج قصور القلب نظرا لازدياد إمكانية حدوث الوذمة الوعائية (تورم سريع تحت الجلد في منطقة كالبلعوم) (راجع قسمي &quot;تحذيرات واحتياطات&quot; و &quot;الأدوية الأخرى و بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ&quot;).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">إذا كانت أي من الحالات التالية تنطبق عليك، فالرجاء أبلغ طبيبك أو الصيدلاني قبل تناول بريتيراكس أرجينين ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بتضيّق الأبهر (أي تضيّق الشريان الرئيسي الخارج من القلب)، أو باعتلال ضخامي في القلب (مرض في عضلة القلب)، أو بتضيّق الشريان الكلوي (تضيق الشريان الذي يغذي الكليتين بالدم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل القلب أو أي مرض قلبي آخر،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل كلوية أو إذا كنت تخضع للديلزة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تشكو من تراجع الرؤية أو من ألم في العينين.&nbsp; قد تكون هذه أعراض تراكم السوائل في الطبقة الوعائية للعين (انصباب مشيمي)، أو لارتفاع الضغط في العين، ومن الممكن أن تحدث في غضون ساعات أو أسابيع من تناول بي بريتيراكس ٥ملغ/١٫٢٥ملغ.&nbsp; وقد تؤدي إلى فقدان البصر إذا تركت دون علاج.&nbsp; إذا كنت مصابا بالحساسية تجاه البنسلين أو السلفاميدات، فربما تكون أكثر عرضة للإصابة به،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مشاكل عضلية، ومن ضمنها الألم، أو المضض، أو الضعف أو التشنجات،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك معدلات مرتفعة بشكل غير طبيعي من هرمون الألدوستيرون في الدم (الأدوستيرونيّة الأوليّة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مرض في الكبد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي مرض من أمراض الكولاجين (مرض جلدي) كالذئبة الحُمامية الجهازية، أو التصلّب الجلدي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التصلّب العصيدي (أي تصلّب الشرايين)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فرط الدُرَيْقات (فرط نشاط الدريقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من النقرس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء السكري،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت خاضعاً لحمية منخفضة الملح أو إذا كنت تستعمل بديلاً للملح يحتوي على البوتاسيوم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتعالج بمادة الليثيوم أو بالأدوية الموفّرة للبوتاسيوم (السبيرونولاكتون أو تريامتيرين) أو مكملات البوتاسيوم لأن استعمالها في نفس الوقت مع بريتيراكس يجب تجنبه (انظر قسم &quot;الأدوية الأخرى و بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة المكملات العشبية أو الغذائية&quot;)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مسنا،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تفاعلات تحسسية ضوئية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بتفاعل تحسسي خطير مترافق بتورّم الوجه، الشفتين، اللسان أو الحلق مما قد يؤدي إلى صعوبة في البلع أو التنفس (وذمة وعائية). وقد يحدث هذا في أي وقت أثناء العلاج. إذا أصبت بأعراض كهذه، فيجب أن تتوقف عن تناول العلاج وتتصل بطبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أياً من الأدوية التالية التي تستعمل لعلاج ضغط الدم المرتفع:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات مستقبلات الأنجيوتنسين &Iota;&Iota; (التي تعرف أيضا باسم مجموعة السارتان &ndash; مثل فالسارتان، تلميسارتان، إربيسارتان)، وخاصة إذا كنت تشكو من اضطرابات كلوية ذات صلة بالسكري.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">قد يقوم طبيبك بالتأكد من وظيفتك الكلوية، ضغط الدم، وكمية الشوارد الكهربائية (مثل البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">راجع أيضاً المعلومات الواردة في قسم &quot;لا تتناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة &quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنتمي إلى العرق الاسود فإن إمكانية الإصابة بالوذمة الوعائية تكون أكثر ارتفاعا والتأثير الخافض للضغط أقل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضا تخضع للتحال الدموي (الديلزة) بإستعمال الأغشية عالية التدفق،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول ايا من الأدوية التالية، فإن أمكانية الإصابة بالوذمة الوعائية ترتفع:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راسيكادوتريل (الذي يستعمل لعلاج الإسهال)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس، إيفيروليموس، تمسيروليموس والأدوية الأخري التي تنتمي إلى مجموعة الأدوية التي تدعى مثبطات الهدف الميكانيكي لرابامايسين -mTOR inhibitors (التي تستعمل لتفادي رفض الأعضاء المزروعة ولعلاج السرطان)،</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ساكوبتريل (الذي يتوفر بجرعة ثابتة بالاشتراك مع فالسارتان)، والذي يستعمل لعلاج قصور القلب المزمن.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp; ليناغلبتين، ساكساغلبتين، سيتاغلبتين، فيلداغلبتين، وكافة الأدوية الأخرى التي تنتمي إلى مجموعة غلبتين (التي تستعمل لعلاج</p><p dir="RTL">السكري).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>الوذمة الوعائية</u></strong></p><p dir="RTL">ذكر حدوث الوذمة الوعائية (تفاعل تحسسي خطير تترافق بتورّم الوجه، الشفتين، اللسان أو الحلق قد تؤدي إلى صعوبة في البلع أو التنفس) لدى المرضى الذي يتلقون علاجا بمثبطات الإنزيم المحوّل للأنجيوتنسين، ومن ضمنها بريتيراكس.</p><p dir="RTL">قد يحدث هذا في أي وقت أثناء العلاج. إذا أصبت بأعراض كهذه، فيجب أن تتوقف عن تناول بريتيراكس وتراجع طبيبك على الفور. راجع القسم ٤.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يجب أن تبلغي طبيبك إذا كنت تعتقدين بأنك حامل (<u>أو أنك قد تصبحين)</u> حاملًا.</p><p dir="RTL">يوصى بعدم تناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة في المراحل المبكرة من الحمل، كما يجب الامتناع عن تناوله إذا كان عمر الحمل أكثر من ثلاثة أشهر نظرًا لإمكانية إضراره بجنينك في حالة الاستخدام بدءًا من هذه المرحلة من الحمل (راجعي قسم &quot;الحمل والإرضاع&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما تتناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة يجب أيضا أن تبلغ طبيبك في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع للتخدير الطبي و/أو لتدخل جراحي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت مؤخراً من إسهال أو قيء أو إذا كنت مصابًا بالجفاف،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لعملية الديلزة أو فصادة الليبوبروتينات المنخفضة الكثافة (الكوليسترول السيء &ndash; LDL) (التي تهدف إلى إزالة الكوليسترول من الدم بالاستعانة بآلة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لعلاج لخفض التحسس بغرض إنقاص تأثيرات الحساسية تجاه لسعات النحل أو الدبابير،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لفحوص طبية تتطلب حقن مادة ملونة ظليلة تحتوي على اليود (مادة تتمكن من إظهار الأعضاء الداخلية للجسم كالكلية أو المعدة في الأشعّة السينية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بتغيرات في الرؤية أو بألم في إحدى عينيك أو كلتيهما أثناء تناول بريتيراكس. فقد يكون هذا علامة لإصابتك بالزرق، ارتفاع الضغط داخل عينك (عينيك). يجب أن تتوقف عن تناول بريتيراكس وأن تستشير طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينصح باستخدام هذا الدواء للمرضى الذين يعانون من عدم تحمل الجالاكتوز ، ونقص خميرة لاكتاز لاب أو بمتلازمة سوء امتصاص الجلوكوز أو الجالاكتوز (أمراض وراثية نادرة).</p><p dir="RTL">يجب أن يعلم الرياضيون أن بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة يحتوي على المادة الفعّالة (إنداباميد)، التي قد تعطي نتيجة إيجابية في فحوصات مراقبة تناول العقاقير المنشطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يجوز على الإطلاق إعطاء بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ للأطفال والمراهقين.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">الأدوية الأخرى و بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة</p><p dir="RTL">أبلغ طبيبك أو الصيدلاني إذا كنت تتناول حالياً، تناولت مؤخّراً أو قد تتناول أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;يجب أن تتجنّب تناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، &nbsp;أقراص ملبّسة أثناء تناول الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (المستعمل في علاج حالات الهوس والاكتئاب)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين (دواء يستعمل لعلاج الضغط المرتفع) إذا كنت غير مصاب بالسكري أو بمشاكل كلوية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرّات البول الموفّرة للبوتاسيوم ( مثل تريامتيرين، أميلوريد)، وأملاح البوتاسيوم، الأدوية الأخرى التي يمكنها زيادة معدل البوتاسيوم في جسمك (مثل الهيبارين الذي يستعمل لتمييع الدم ومنع التخثر؛ وترايميثوبريم وكوتريموكسازول المعروف أيضا باسم ايميثوبريم / سلفاميثوكسازول لعلاج حالات العدوى البكترية)،</p><ul><li dir="RTL">إستراموستين (المستعمل في علاج السرطان)،</li><li dir="RTL">الأدوية الأخرى التي تستعمل لعلاج ضغط الدم المرتفع: مثبطات الإنزيم المحول للأنجيوتنسين وحاصرات مستقبلات الأنجيوتنسين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤثر تناول الأدوية الأخرى على العلاج بتناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ. قد يحتاج طبيبك إلى تغيير جرعتك و/أو اتخاذ احتياطات أخرى. يجب إبلاغ طبيبك إذا كنت تتناول حاليًا أياً من الأدوية التالية، لاتخاذ الاحتياطات الخاصة:</p><ul><li dir="RTL">الأدوية الأخرى لعلاج ارتفاع ضغط الدم، بما فيها حاصرات مستقبلات الأنجيوتنسين &Iota;&Iota; أو أليسكيرين (راجع أيضاً المعلومات الواردة في قسم &quot;لا تتناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة &quot; وقسم &quot; تحذيرات واحتياطات&quot;)، أو المدرات (الأدوية التي تزيد من كمية البول الذي تنتجه الكليتان)،</li><li dir="RTL">الأدوية الموفّرة للبوتاسيوم المستعملة في علاج قصور القلب: إيبليرينون وسبيرونولاكتون بجرعات تتراوح بين ١٢٫٥ ملغم و٥٠ ملغم يوميا.</li><li dir="RTL">الأدوية، التي كثيرا ما تستعمل لعلاج الإسهال (راسيكادوتريل) أو تفادي رفض الأعضاء المزروعة (سيروليموس، إيفيروليموس، تيمسيروليموس وأدوية أخرى من الأدوية التي تدعى مثبطات m-Tor).&nbsp; راجع قسم &nbsp;&quot;تحذيرات واحتياطات&quot;،</li><li dir="RTL">ساكوبتريل / فالسارتان (الذي يستعمل لعلاج قصور القلب المزمن). راجع قسم &quot; لا تتناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة&quot; وقسم &quot; تحذيرات واحتياطات&quot;</li><li dir="RTL">أدوية التخدير،</li><li dir="RTL">العوامل الظليلة التي تحتوي على اليود،</li><li dir="RTL">المضادات الحيوية التي تستعمل لعلاج حالات العدوى البكتيرية (مثل: موكسيفلوكساسين، سباروفلوكساسين، إريثروميسين عن طريق الحقن)،</li><li dir="RTL">ميثادون (يستعمل لعلاج الإدمان)،</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروكايين آميد (لعلاج عدم انتظام ضربات القلب)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلوبورينول (لعلاج النقرس)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهيستامين التي تستعمل التفاعلات التحسسية مثل حمى القشّ &nbsp;(مثل: ميزولاستين، ترفينادين أو آستيميزول)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات المستعملة لعلاج اضطرابات مختلفة بما فيها الربو الشديد أو التهاب المفاصل الروماتويدي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كابتات المناعة المستعملة في علاج أمراض المناعة الذاتية، أو بعد عمليات نقل الأعضاء لتفادي عوارض الرفض (مثل</p><p dir="RTL">&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;السيكلوسبورين، تاكروليموس)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين (لعلاج أنواع خاصة من الملاريا)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنتاميدين (لعلاج ذات الرئة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حقن أملاح الذهب (لعلاج التهاب المفاصل الروماتويدي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينكامين (لعلاج أعراض اضطرابات الإدراك لدى المتقدمين بالسن بما فيها مشاكل الذاكرة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ببريديل (المُستخدم لعلاج الذبحة الصدرية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة في علاج عدم انتظام ضربات القلب (مثل: الكينيدين، هيدروكينيدين، &nbsp;ديزوبيراميد، أميودارون، &nbsp;سوتالول، إيبوتيليد، دوفيتيليد، مركبات الديجيتال، بريتيليوم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيزابريد، ديفيمانيل (لعلاج الاضطرابات المَعِدية والهضمية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين أو غيره من الجليكوسيدات القلبية (لعلاج الاضطرابات القلبية)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باكلوفين (لعلاج تيبس العضلات الحادث بسبب أمراض مثل التصلب المتعدد)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة في علاج داء السكري مثل الأنسولين والمتفورمين أو الغليبتين،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكالسيوم بما في ذلك مكمّلات الكالسيوم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المسهّلات المنشطة (مثل نبات السَنا)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية (مثل إيبوبروفين)، أو الجرعات المرتفعة من الساليسيلات (مثل حمض الأستيل ساليسيليك (المادة التي توجد في العديد من الأدوية التي تستعمل لتخفيف الألم وخفض الحرارة، بالإضافة إلى منع تشكل الخثرات)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آمفوتيريسين B عن طريق الحقن (لعلاج حالات العدوى الفطرية الشديدة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة في علاج الاضطرابات النفسية مثل الاكتئاب، أو القلق، أو الفصام (مثل مضادات الاكتئاب الثلاثية الحلقات، أو مضادات الذهان (مثل أميسولبريد، ٍسولبيريد، سولتوبريد، تيابريد، هالوبيريدول، دروبيريدول)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيتراكوساكتيد (لعلاج داء كرون)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترايميثوبريم (لعلاج حالات العدوى).&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موسّعات الأوعية الدموية بما فيها النترات (المستحضرات التي تسبب توسّع الأوعية الدمويّة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تستعمل لعلاج ضغط الدم المنخفض، الصدمة أو الربو (مثل إفدرين، نورأدرنالين أو أدرينالين).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>تناول </strong><strong>بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة مع الطعام والشراب والكحول</strong></p><p>من المفضّل أن يتم تناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة قبل الطعام.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">إذا كنت حاملا أو مرضعا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، فاستشيري طبيبك أو الصيدلاني قبل</p><p dir="RTL">تناول أي دواء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الحمل</u></strong></p><p dir="RTL">يجب أن تبلغي طبيبك إذا كنت تعتقدين بأنك حامل (أو أنك قد تصبحين) حاملًا. سيوصيك طبيبك في الأحوال الطبيعية بالتوقف عن تناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، &nbsp;أقراص ملبّسة قبل حدوث الحمل أو بمجرد أن تتأكدي من حدوثه.</p><p dir="RTL">وسوف ينصحك بتناول دواء آخر بدلاً من بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة.</p><p dir="RTL">&nbsp;يوصى بعدم تناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة في المراحل المبكرة من الحمل، كما يجب الامتناع عن تناوله إذا كان عمر الحمل أكثر من ثلاثة أشهر نظراً لإمكانية إحداثه تأثيرات خطيرة على الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الإرضاع</u></strong></p><p dir="RTL">يجب ألا تتناولي بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة إذا كنت ترضعين طفلك.</p><p dir="RTL">يجب أن تبلغي طبيبك إذا كنت ترضعين طفلك أو إذا كنت على وشك البدء بإرضاعه.</p><p dir="RTL">لا يوصى بإعطاء بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة &nbsp;للأمهات المرضعات، ويمكن لطبيبك أن يختار لك علاجا آخرا إذا كنت ترغبين بالإرضاع، وخاصة إذا كان طفلك حديث الولادة أو خدبجا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشيري طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قيادة السيارات وتشغيل الآلات</u></p><p dir="RTL">بشكل عام، لا يؤثر بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة على اليقظة ولكن بعض ردود الفعل المختلفة كالشعور بالدوخة أو التعب والناجمة عن انخفاض الضغط الشرياني قد تحدث عند بعض المرضى. نتيجة لهذا، قد تقل قدرتك على قيادة السيارات أو تشغيل الآلات.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ &nbsp;على اللاكتوز أحادي الماء.</strong></p><p dir="RTL">إذا كان طبيبك قد أخبرك أنك مصاب بعدم تحمّل أنواع معينة من السكر، فاتصل به قبل أن تتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي </strong><strong>بريتيراكس ٢٫٥ملغ/٠٫٦٢٥ ملغ </strong><strong>على الصوديوم</strong></p><p dir="RTL">يحتوي بريتيراكس ٢٫٥ملغ/٠٫٦٢٥ ملغ على أقل من 1 ممول من الصوديوم (23 ملغ) في كل حبة، ولذا يمكن اعتباره &rsquo;خاليا من الملح&lsquo;.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دومًا على تناول هذا الدواء ملتزمًا تمامًا بتوصيات طبيبك. وفي حال الشك استشر طبيبك أو الصيدلاني. يبلغ مقدار الجرعة الموصى بها &nbsp;قرص واحد يومياً. قد يقرر طبيبك أن يرفع تلك الجرعة إلى قرصين يومياً، أو أن يُعدّل الجرعة إن كنت تشكو من قصور كلوي.</p><p dir="RTL">يُفضل تناول القرص صباحًا قبل وجبة الإفطار، وأن يُبتلع مع كأس من الماء .</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp; إذا تناولت جرعة أكبر مما ينبغي من </strong><strong>بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة</strong></p><p><strong>ا</strong>ستشر فورا طبيبك أو الصيدلاني.</p><p>إذا تناولت عددًا كبيرًا من الأقراص، فاتصل على الفور بطبيبك أو بقسم الطوارئ في أقرب مستشفى. غالباً ما ستصاب بهبوط في ضغط الدم في حال زيادة الجرعة. إذا حدث هبوط شديد في ضغط الدم (وترافق مع غثيان، تقيؤ، تشنجات، دوخة، شعور بالنعاس، ارتباك ذهني، تغيرات في كمية البول الذي تنتجه الكليتان)،فمن الممكن معاكسته &nbsp;إباستلقاء المريض مع رفع الساقين للأعلى .</p><p dir="RTL"><strong>إذا نسيت تناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة</strong></p><p dir="RTL">من المهم جدًا أن تتناول دواءك كل يوم لأن العلاج المنتظم أكثر فعالية. ولكن إذا نسيت تناول إحدى جرعات بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، &nbsp;أقراص ملبّسة فعليك ببساطة أن تتناول جرعتك الاعتيادية صباح اليوم التالي كالمعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة للتعويض عن الجرعة التي نسيت تناولها.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ج- إذا توقفت عن تناول بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة</strong></p><p dir="RTL">نظرًا لأن علاج الضغط الشرياني المرتفع علاج طويل الأمد، يجب أن تستشير طبيبك قبل التوقف عن تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية تتعلق باستعمال هذا الدواء، فاسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء &nbsp;آثارًا جانبية، بالرغم من عدم حدوثها لدى كافة الأفراد.</p><p dir="RTL"><strong>توقف عن تناول المستحضر الدوائي وراجع طبيبك على الفور، إذا أصبت بأي من الأثار الجانبية التالية التي قد تكون خطيرة: </strong><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار شديد أو إغماء بسبب هبوط ضغط الدم (شائع - قد يصيب حتى ١ من ١٠ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج قصبي (ضيق الصدر، أزيز وضيق النفس (غير شائعة) (قد تصيب حتى ١ من ١٠٠ شخص)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه، أو الشفتين، أو الفم، أو اللسان أو الحلق، صعوبة التنفس(وذمة وعائية) (راجع القسم &quot;تحذيرات واحتياطات&quot; (غير شائعة) (قد تصيب حتى ١ من كل ١٠٠ شخص)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة تشمل الحمامى متعددة الأشكال (طفح جلدي كثيرا ما يبدأ ببقع &nbsp;حمراء حاكة على الوجه، الذراعين أو الساقين) أو طفح جلدي شديد، شرى، احمرار الجلد في كافة أنحاء الجسم، حكة شديدة، تشكل نفاطات، تقشر الجلد وتورّمه، التهاب الأغشية المخاطية (متلازمة ستيفنس جونسن) أو تفاعلات تحسسية أخرى (نادرة جدا) (قد تصيب حتى ١من كل ١٠٠٠٠شخص)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات قلبية وعائية (عدم انتظام ضربات القلب، خناق الصدر (ألم في الصدر ينتشر&nbsp; إلى الفك والظهر، ويحدث بسبب الجهد الجسدي)، نوبة قلبية) (نادرة جدا) (قد تصيب حتى١ من كل ١٠٠٠٠ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في الذراعين أو الساقين، أو مشاكل عند التكلم قد تكون علامة لحادث وعائي دماغي ممكن الحدوث (نادرة جدا) (قد تصيب حتى١ من كل ١٠٠٠٠ شخص)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس الذي قد يسبب ألما شديدا جدا في البطن والظهر يرافقه شعور بالإعياء (نادر جدا) (قد يصيب حتى١ من كل ١٠٠٠٠ شخص)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو العينين (يرقان) الذي قد يكون علامة لالتهاب الكبد (نادر جدا - قد يصيب حتى١ من كل ١٠٠٠٠شخص)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب غير منتظمة المهددة للحياة (معدّل غير معروف)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب عصبي ناجم عن إصابة كبدية (اعتلال الدماغ كبدي المنشأ) (معدّل غير معروف ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف، تشنجات، مضض العضلات أو ألمها، وبشكل خاص، إذا شعرت في نفس الوقت بتوعك أو ارتفاع في درجة الحرارة، فقد يكون ذلك بسبب التدرّك العضلي غير الطبيعي (معدّل حدوثها غير معروف).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن تشمل الآثار الجانبية ما يلي وذلك حسب الترتيب التنازلي لمعدل حدوثها:</p><p dir="RTL">&nbsp;</p><p dir="RTL">- آثار شائعة الحدوث (قد تصيب حتى من ١ من كل ١٠ أشخاص):</p><p dir="RTL">تفاعلات جلدية لدى الأفراد المعرضين للتفاعلات التحسسية والربوية، صداع، دوار، دوخة، نخز، اضطرابات بصرية، طنين (سماع ضجيج في الأذنين)، سعال، ضيق النفس (صعوبة التنفس)، اضطرابات معِدية مِعَوية (غثيان، ألم في المعدة، فقد الشهية، قيء، ألم في البطن، اضطراب حسّ التذوّق، عسر الهضم أو صعوبة الهضم، إسهال، إمساك)، تفاعلات تحسسية (مثل الطفح الجلدي، الحكة)، تشنجات، شعور بالتعب</p><p dir="RTL">- آثار غير شائعة الحدوث (قد تصيب حتى &nbsp;١ من كل١٠٠ شخص): تبدلات مزاجية، اضطراب النوم، شرى، فرفرية (نقاط حمراء على الجلد)، فقاعات، اضطرابات كلوية، عنّة، (عدم التمكن من تحقيق الانتصاب أو المحاقظة عليه)، &nbsp;تعرّق، زيادة كبيرة في اليوزينيات (نوع من خلايا الدم البيضاء)، تغير في المعايير المخبرية: ارتفاع معدل البوتاسيوم القابل للتراجع عند إيقاف العلاج، انخفاض معدل الصوديوم في الدم مما قد يسبب الجفاف وانخفاض الضغط الشرياني، نعاس، إغماء، خفقان القلب (الشعور بضربات قلبك)، تسرع القلب (ضربات قلب سريعة)، نقص شديد في معدل السكر في الدم في حال مرضى السكر، التهاب الأوعية الدموية، جفاف الفم، تفاعلات تحسسية ضوئية (زيادة حساسسية الجلد للشمس)، ألم المفاصل، ألم العضلات، ألم الصدر، إعياء، وذمة محيطية، حمى، ارتفاع معدل البولة في الدم، ارتفاع معدل الكرياتينين في الدم، سقوط.</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار نادرة (قد تصيب حتى ١ من كل ١٠٠٠ شخص):</p><p dir="RTL">تدهور حالة الصدفية، تغيّر في المعايير المخبرية: انخفاض معدل الكلور في الدم، انخفاض معدل المغنيزيوم في الدم، ارتفاع معدّل الخمائر الكبدية، ارتفاع معدّل بيليروبين المصل، تعب. ، تبيّغ، تناقص معدل إنتاج البول أو انعدامه، قصور كلوي حادّ.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بول مركّز، الغثيان أو التقيؤ، تشنج عضلي، ارتباك ونوبات. قد تكون هذه الأعراض ناجمة عن حالة الإفراز غير المناسب من الهرمون المضادّ للإدرار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">- &nbsp;&nbsp;&nbsp;&nbsp; آثار نادرة جدًا (قد تصيب حتى &nbsp;من ١ من كل ١٠٠٠٠ شخص): ارتباك، ذات الرئة اليوزينية (شكل نادر من ذات الرئة)، التهاب الأنف (احتقان الأنف أو سيلانه)، مشاكل كلوية شديدة، تغيرات في القيم الدموية مثل انخفاض عدد خلايا الدم البيضاء والحمراء، انخفاض الهيموغلوبين، &nbsp;تناقص عدد الصفيحات الدموية، ارتفاع معدل الكالسيوم في الدم، خلل في الوظيفة الكبدية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار ذات معدّل غير معروف (لا يمكن تقدير معدّل حدوثها بالاستناد إلى البيانات المتوفرة في الوقت الحاضر): تبدلات غير طبيعية في مخطط القلب الكهربائي، تغيرات في المعايير المخبرية: ارتفاع معدلات حمض اليورريك وارتفاع معدلات السكر في الدم، قصر النظر (حسر البصر)، تشوش الرؤية، اضطراب الرؤية، ، تراجع الرؤية أو ألم العين بسبب الضغط المرتفع (علامات محتملة لتراكم السوائل في الطبقة الوعائية للعين (الانصباب المشيمي)، أو الغلوكوما (الزرق) الحاد مغلق الزاوية)، تبقّع، خدر وألم في أصابع اليدين أو القدمين (متلازمة رينو). إذا كنت تعاني من الذئبة الحمامية الجهازية (أحد أمراض الكولاجين)، فقد تزداد شدتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن تحدث اضطرابات كلوية، كبدية أو بنكرياسية مع تغير في المعايير الحيوية (فحوصات الدم). قد يطلب طبيبك إجراء فحوص الدم لمراقبة حالتك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ به بعيدًا عن مرأى عيون الأطفال ومتناول أيديهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المذكور على العلبة الخارجية وعلى حاوي الأقراص. تاريخ انتهاء الصلاحية هو آخر يوم من الشهر المُشار إليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ العبوة مغلقة بإحكام لتحميها من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية في مياه المجاري العامة أو مع قمامة المنزل.&nbsp; اسأل الصيدلاني عن طريقة</p><p dir="RTL">التخلص من الأدوية التي لم تعد تستعملها. هذه الإجراءات تساعد على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هي مكونات بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادتان الفعالتان هما بيريندوبريل أرجينين و إنداباميد. كل قرص ملبّس يحتوي على ٢٫٥ ملغ من البيريندوبريل أرجينين (أي ١٫٦٩٧٥ ملغ من البيريندوبريل) و٠٫٦٢٥ ملغ من الإنداباميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى في داخل القرص هي لاكتوز وحيد الماء، ستيارات المغنيزيوم (E470B)، مالتوديكسترين، السيليكا الغروانيّة اللامائيّة (E551)، غليكولات النشاء الصودي (النوع A)، وفي غلاف القرص غليسيرول (E422)، هيبروملّوز (E464)، ماكروغول ٦٠٠٠، ستيارات المغنيزيوم (E470B)، ثاني أوكسيد التيتانيوم (E171).</p><p dir="RTL">&nbsp;</p><p><!--[if !supportLists]--></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">كيف يبدو<em> </em>بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ، أقراص ملبّسة &nbsp;وما هي محتويات العبوة الخارجية؟</p><p dir="RTL" style="text-align:right">بريتيراكس ٢٫٥ ملغ/٠٫٦٢٥ ملغ هي أقراص بيضاء اللون متطاولة الشكل ملبّسة. وتحتوي على خط مركزي على كل من وجهيها. كل قرص ملبّس يحتوي على ٢٫٥ ملغ من البيريندوبريل أرجينين وعلى ٠٫٦٢٥ملغ من الإنداباميد. الخط الفاصل الموجود على القرص لا يقصد منه تقسيم القرص.</p><p dir="RTL" style="text-align:right">تتوفر أقراص بريتيراكس أرجينين ٢٫٥ ملغ/٠٫٦٢٥ ملغ في عبوات تحتوي على &nbsp;٣٠قرصاً.</p><p dir="RTL" style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجهة الحاملة لإجازة التسويق:</strong></p><p dir="RTL">مختبرات سيرفييه - فرنسا</p><p dir="RTL">Les Laboratoires Servier</p><p dir="RTL">50, rue Carnot</p><p dir="RTL">92284 Suresnes cedex - France</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة:</strong><strong> </strong></p><p dir="RTL">سرفييه (آيرلندا) للصناعات المحدودة</p><p dir="RTL">Servier (Ireland) Industries Ltd</p><p dir="RTL">Gorey Road</p><p dir="RTL">Arklow - Co. Wicklow &ndash; Ireland</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تمت التعبئة بواسطة شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">مبنى رقم 6979 ، المدينة الصناعية بحائل، حائل 55414</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">هاتف: 966112687900+</p><p>فاكس: 966112687911+</p><p dir="RTL">للحصول على أي معلومات تتعلق بهذا الدواء، الرجاء الاتصال بالوكيل المحلي للجهة الحاملة لإجازة التسويق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:581px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المملكة العربية السعودية</strong></p><p dir="RTL">المكتب العلمي لشركة سيرفير العربية السعودية</p><p dir="RTL">3533 الحوي، حي حطين، مكتب 101</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">هاتف: ٩٦٦١١2522330+</p><p dir="RTL">البريد الالكتروني: regulatory.sa1@servier.com</p></td><td style="vertical-align:top"><p dir="RTL"><strong>بلدان الخليج</strong></p><p dir="RTL">المكتب العلمي لمختبرات سرفييه</p><p dir="RTL">ص.ب. ١٥٨٦، الطابق ١٥، برج أرينكو، مدينة دبي الإعلامية</p><p dir="RTL">طريق الشيخ زايد، دبي، الإمارات العربية المتحدة</p><p dir="RTL">هاتف: ٩٧١٤٣٣٢٩٩٠٣+</p><p dir="RTL">البريد الإلكتروني: magdy.abdou@servier.com</p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05-2022

. للإبلاغ عن التأثير(ات) الجانبية:

•	المملكة العربية السعودية
 - المركز الوطني للتيقظ الدوائي (NPC)
- للاتصال بالرقم الموحد للهيئة العامة للغذاء والدواء 19999
- البريد الالكتروني: npc.drug@sfda.gov.sa
- الموقع الالكتروني: https://ade.sfda.gov.sa/ 

•	دول الخليج العربي الأخرى:
- الرجاء الاتصال بالسلطات المختصة ذات الصلة.

و. مجلس وزراء الصحة العرب :
إن هذا لدواء
الدواء مستحضر يؤثر على صحّتك، واستهلاكه خلافاً للتعليمات يعرّضك للخطر.
تقيّد بوصفة الطبيب، وبطريقة الاستعمال المدوّنة، وبتعليمات الصيدلاني الذي صرّف لك الدواء.
	فالطبيب والصيدلاني هما الخبيران بالدواء ونفعه وضرره.
	لا تقطع مدة العلاج المحدّدة لك من تلقاء نفسك.
	لا تكرر استعمال نفس الدواء دون مراجعة الطبيب.
	لا تدع الأدوية بمتناول أيدي الأطفال.
مجلس  الصحّة لدول مجلس التعاون
واتّحاد الصيادلة العرب



هـ. هذه النشرة لمعلومات المريض حائزة على موافقة الهيئة العامة للغذاء والدواء في المملكة العربية السعودية


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Preterax 2.5mg/0.625mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains 1.6975 mg perindopril corresponding to 2.5 mg perindopril arginine and 0.625 mg indapamide.

Excipient with known effect: 74.455 mg lactose monohydrate
For the  full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
White, rod-shaped film-coated tablet with an embossed line on both faces.

The score line is not intended for breaking the tablet.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preterax 2.5mg/0.625mg &nbsp;is indicated in essential hypertension in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The usual dose is<strong><em> </em></strong>one&nbsp; Preterax 2.5mg/0.625mg film-coated tablet per day as a single dose, preferably to be taken in the morning and before a meal. If blood pressure is not controlled after one month of treatment, the dose can be doubled<em>.</em></p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>&nbsp;Elderly (see section 4.4)</em></p><p>Treatment should be started at the normal dose of one&nbsp; Preterax 2.5mg/0.625mg film-coated tablet per day.</p><p>&nbsp;</p><p><em>Renal impairment (see section 4.4)</em></p><p>In severe renal impairment (creatinine clearance below 30 ml/min), treatment is contraindicated.</p><p>In patients with moderate renal impairment (creatinine clearance 30-60 ml/min), the maximum dose should be one tablet of &nbsp;Preterax 2.5mg/0.625mg per day.</p><p>In patients with creatinine clearance greater than or equal to 60 ml/min, no dose modification is required.</p><p>Usual medical follow-up will include frequent monitoring of creatinine and potassium.</p><p>&nbsp;</p><p><em>Hepatic impairment (see sections 4.3, 4.4 and 5.2)</em></p><p>In severe hepatic impairment, treatment is contraindicated.</p><p>In patients with moderate hepatic impairment, no dose modification is required.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of perindopril arginine/indapamide in the paediatric population have not yet been established. No data are available.</p><p>Preterax &nbsp;2.5mg/0.625mg should not be used in children and adolescents.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Linked to perindopril
-	Hypersensitivity to the active substance  or to any other ACE inhibitor
-	History of angioedema (Quincke’s oedema) associated with previous ACE inhibitor therapy (see section 4.4)
-	Hereditary/idiopathic angioedema
-	Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
-	Concomitant use of Preterax 2.5mg/0.625mg with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²) (see sections 4.5 and 5.1).
-	Concomitant use with sacubitril/valsartan therapy. Preterax 2.5mg/0.625mg must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan. (see sections 4.4 and 4.5). 
-	Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see section 4.5),
-	Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see section 4.4).

Linked to indapamide
-	Hypersensitivity to the active substance  or to any other sulphonamides
-	Severe renal impairment (creatinine clearance below 30 ml/min)
-	Hepatic encephalopathy
-	Severe hepatic impairment
-	Hypokalaemia

Linked to Preterax 2.5mg/0.625mg
-	Hypersensitivity to any of the excipients listed in section 6.1

Due to the lack of sufficient therapeutic experience, Preterax 2.5mg/0.625mg should not be used in:
-	Dialysis patients
-	Patients with untreated decompensated heart failure

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Special warnings</strong></p><p>&nbsp;</p><p><em><u>Common to perindopril and indapamide</u></em></p><p>&nbsp;</p><p>For the low-dose combination &nbsp;Preterax 2.5mg/0.625mg no significant reduction of adverse drug reactions as compared to the lowest approved dosages of the individual monocomponents has been shown except for hypokalaemia (see section 4.8). An increased frequency of idiosyncratic reactions can not be excluded if the patient is simultaneously exposed to two antihypertensive agents new to him. To minimise this risk the patient should be carefully monitored.</p><p>&nbsp;</p><p><em>Lithium</em></p><p>The combination of lithium and the combination of perindopril and indapamide is usually not recommended (see section 4.5).</p><p>&nbsp;</p><p><em><u>Linked to perindopril</u></em></p><p>&nbsp;</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</em></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em>&nbsp;</em></p><p><em>P</em><em>otassium-sparing drugs , potassium supplements or potassium-containing salt substitutes</em></p><p>The combination of perindopril and potassium-sparing drugs , potassium supplements or potassium-containing salt substitutes&nbsp; is usually not recommended (see section 4.5).</p><p>&nbsp;</p><p><em>Neutropenia/agranulocytosis/thrombocytopenia/anaemia</em></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Perindopril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy. If perindopril is used in such patients, periodical monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection (e.g. sore throat, fever) (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><em>Renovascular hypertension:</em></p><p>There is an increased risk of hypotension and renal insufficiency when patient with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors (see section 4.3). Treatment with diuretics may be a contributory factor. Loss of renal function may occur with only minor changes in serum creatinine even in patients with unilateral renal artery stenosis.</p><p>&nbsp;</p><p><em>Hypersensitivity/angioedema</em></p><p>Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin converting enzyme inhibitors, including&nbsp;perindopril (see section 4.8). This may occur at any time during treatment. In such cases perindopril&nbsp;should be discontinued promptly and appropriate monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patient. In those instances where swelling has been confined to the face and lips the condition generally resolved without treatment, although antihistamines have been useful in relieving symptoms.</p><p>Angioedema associated with laryngeal oedema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, which may include subcutaneous epinephrine solution 1:1000 (0.3&nbsp;ml to 0.5&nbsp;ml) and/or measures to ensure a patent airway, should be administered promptly.</p><p>&nbsp;</p><p>Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.</p><p>&nbsp;</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE&nbsp;inhibitor (see section 4.3).</p><p>&nbsp;</p><p>Intestinal angioedema has been reported rarely in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan, or ultrasound or at surgery and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.</p><p>&nbsp;</p><p>The combination of perindopril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see section 4.3). Sacubitril/valsartan must not be initiated until 36 hours after taking the last dose of perindopril therapy. If treatment with sacubitril/valsartan is stopped, perindopril therapy must not be initiated until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.5). Concomitant use of ACE inhibitors with NEP inhibitors (e.g. racecadotril), mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk of angioedema (e.g. swelling of the airways or tongue, with or without respiratory impairment) (see section 4.5). Caution should be used when starting racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) in a patient already taking an ACE inhibitor.</p><p>&nbsp;</p><p><s>&nbsp;</s></p><p><em>Anaphylactoid reactions during desensitisation</em></p><p>There have been isolated reports of patients experiencing sustained, life-threatening anaphylactoid reactions while receiving ACE inhibitors during desensitisation treatment with hymenoptera (bees, wasps) venom. ACE inhibitors should be used with caution in allergic patients treated with desensitisation, and avoided in those undergoing venom immunotherapy. However these reactions could be prevented by temporary withdrawal of ACE inhibitor for at least 24 hours before treatment in patients who require both ACE inhibitors and desensitisation.</p><p>&nbsp;</p><p><em>Anaphylactoid reactions during LDL apheresis</em></p><p>Rarely, patients receiving ACE inhibitors during low density lipoprotein (LDL)-apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE-inhibitor therapy prior to each apheresis.</p><p><em>&nbsp;</em></p><p><em>Haemodialysis patients</em></p><p>Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g., AN 69&reg;) and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p>&nbsp;</p><p><em>Primary aldosteronism:</em></p><p>Patients with primary hyperaldosteronism generally will not respond to anti-hypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of this product is not recommended.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><em><u>L</u></em><em><u>inked to indapamide</u></em></p><p>&nbsp;</p><p><em>Hepatic encephalopathy</em></p><p>When liver function is impaired, thiazide diuretics and thiazide-related diuretics may cause, particulary in case of electrolyte imbalance, hepatic encephalopathy which can progress to hepatic coma. Administration of the diuretic should be stopped immediately if this occurs.</p><p>&nbsp;</p><p><em>Photosensitivity</em></p><p>Cases of photosensitivity reactions have been reported with thiazides and related thiazides diuretics (see section 4.8). If photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.</p><p><em><u>&nbsp;</u></em></p><p><strong>Precautions for use</strong></p><p>&nbsp;</p><p><em><u>Common to perindopril and indapamide</u></em></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In cases of severe renal impairment (creatinine clearance &lt; 30 ml/min), treatment is contraindicated.</p><p>In certain hypertensive patients without pre-existing apparent renal lesions and for whom renal blood tests show functional renal insufficiency, treatment should be stopped and possibly restarted either at a low dose or with one constituent only.</p><p>In these patients usual medical follow-up will include frequent monitoring of potassium and creatinine, after two weeks of treatment and then every two months during therapeutic stability period. Renal failure has been reported mainly in patients with severe heart failure or underlying renal failure including renal artery stenosis.</p><p>The drug is usually not recommended in case of bilateral renal artery stenosis or a single functioning kidney.</p><p>&nbsp;</p><p><em>Hypotension and water and electrolyte depletion</em></p><p>There is a risk of sudden hypotension in the presence of pre-existing sodium depletion (in particular in individuals with renal artery stenosis). Therefore systematic testing should be carried out for clinical signs of water and electrolyte depletion, which may occur with an intercurrent episode of diarrhoea or vomiting. Regular monitoring of plasma electrolytes should be carried out in such patients.</p><p>Marked hypotension may require the implementation of an intravenous infusion of isotonic saline.</p><p>Transient hypotension is not a contraindication to continuation of treatment. After re‑establishment of a satisfactory blood volume and blood pressure, treatment can be started again either at a reduced dose or with only one of the constituents.</p><p>&nbsp;</p><p><em>Potassium levels</em></p><p>The combination of perindopril and indapamide does not prevent the onset of hypokalaemia particularly in diabetic patients or in patients with renal failure. As with any antihypertensive agent in combination with a diuretic, regular monitoring of plasma potassium levels should be carried out.</p><p>&nbsp;</p><p><em>Excipients</em></p><p>Preterax 2.5mg/0.625mg should not be administered to patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.</p><p>&nbsp;</p><p>Level of sodium</p><p>Preterax 2.5mg/0.625mg contains less than 1 mmol sodium (23 mg) per tablet, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><em><u>Linked to perindopril</u></em></p><p>&nbsp;</p><p><em>Cough</em></p><p>A dry cough has been reported with the use of angiotensin converting enzyme inhibitors. It is characterised by its persistence and by its disappearance when treatment is withdrawn. An iatrogenic aetiology should be considered in the event of this symptom. If the prescription of an angiotensin converting enzyme inhibitor is still preferred, continuation of treatment may be considered.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The efficacy and tolerability of perindopril in children and adolescents, alone or in combination, have not been established.</p><p>&nbsp;</p><p><em>Risk of arterial hypotension and/or renal insufficiency (in cases of cardiac insufficiency, water and electrolyte depletion, etc...)</em></p><p>Marked stimulation of the renin-angiotensin-aldosterone system has been observed particularly during marked water and electrolyte depletions (strict sodium restricted diet<strong><em> </em></strong>or prolonged diuretic treatment), in patients whose blood pressure was initially low, in cases of renal artery stenosis, congestive heart failure or cirrhosis with oedema and ascites.</p><p>The blocking of this system with an angiotensin converting enzyme inhibitor may therefore cause, particularly at the time of the first administration and during the first two weeks of treatment, a sudden drop in blood pressure and/or an increase in plasma levels of creatinine, showing a functional renal insufficiency. &nbsp;Occasionally this can be acute in onset, although rare, and with a variable time to onset.</p><p>In such cases, the treatment should then be initiated at a lower dose and increased progressively.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Renal function and potassium levels should be tested before the start of treatment. The initial dose is subsequently adjusted according to blood pressure response, especially in cases of water and electrolyte depletion, in order to avoid sudden onset of hypotension.</p><p><em>&nbsp;</em></p><p><em>Atherosclerosis</em></p><p>The risk of hypotension exists in all patients but particular care should be taken in patients with ischaemic heart disease or cerebral circulatory insufficiency, with treatment being started at a low dose.</p><p>&nbsp;</p><p><em>Renovascular hypertension</em></p><p>The treatment for renovascular hypertension is revascularisation. Nonetheless, angiotensin converting enzyme inhibitors can be beneficial in patients presenting with renovascular hypertension who are awaiting corrective surgery or when such a surgery is not possible.</p><p>If Preterax 2.5mg/0.625mg is prescribed to patients with known or suspected renal artery stenosis, treatment should be started in a hospital setting<strong><em> </em></strong>at a low dose and renal function and potassium levels should be monitored, since some patients have developed a functional renal insufficiency which was reversed when treatment was stopped.</p><p>&nbsp;</p><p><em>Cardiac failure/severe cardiac insufficiency</em></p><p>In patients with severe cardiac insufficiency (grade IV), treatment should be started under medical supervision with a reduced initial dose. Treatment with beta-blockers in hypertensive patients with coronary insufficiency should not be stopped: the ACE inhibitor should be added to the beta-blocker.</p><p><em>Diabetic patients</em></p><p>In patients with insulin dependent diabetes mellitus (spontaneous tendency to increased levels of potassium), treatment should be started under medical supervision with a reduced initial dose.</p><p>The glycaemia levels should be closely monitored in diabetic patients previously treated with oral antidiabetic drugs or insulin, namely during the first month of treatment with an ACE inhibitor (see section 4.5).</p><p>&nbsp;</p><p><em>Ethnic differences</em></p><p>As with other angiotensin converting enzyme inhibitors, perindopril is apparently less effective in lowering blood pressure in black people than in non‑blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p>&nbsp;</p><p><em>Surgery / anaesthesia</em></p><p>Angiotensin converting enzyme inhibitors can cause hypotension in cases of anaesthesia, especially when the anaesthetic administered is an agent with hypotensive potential.</p><p>It is therefore recommended that treatment with long-acting angiotensin converting enzyme inhibitors such as perindopril should be discontinued where possible one day before surgery.</p><p>&nbsp;</p><p><em>Aortic or mitral valve stenosis / hypertrophic cardiomyopathy</em></p><p>ACE inhibitors should be used with caution in patient with an obstruction in the outflow tract of the left ventricle.</p><p>&nbsp;</p><p><em>Hepatic failure</em></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up (see section 4.8).</p><p>&nbsp;</p><p><em>Hyperkalaemia</em></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including perindopril, ACE inhibitors can cause hyperkalaemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. Risk factors for the development of hyperkalaemia include those with renal insufficiency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis and concomitant use of potassium-sparing diuretics (e.g. spironolactone, eplerenone, triamterene, amiloride&hellip;), potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g. heparins, co-trimoxazole also known as trimethoprim/sulfamethoxazole, other&nbsp; ACE inhibitors, angiotensin-II receptor antagonists, acetylsalicylic acid &sup3; 3 g/day, COX-2 inhibitors and non-selective NSAIDs, immunosuppressant agents such as ciclosporin or tacrolimus, trimethoprim) and especially aldosterone antagonists or angiotensin-receptor blockers. The use of potassium supplements, potassium-sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalaemia can cause serious, sometimes fatal arrhythmias. Potassium-sparing diuretics and angiotensin-receptor blockers should be used with caution in patients receiving ACE inhibitors, and serum potassium and renal function should be monitored. If concomitant use of the above-mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium (see section 4.5).</p><p>&nbsp;</p><p><em><u>Linked to indapamide</u></em></p><p>&nbsp;</p><p><em>Water and electrolyte balance</em></p><p><em>Sodium levels</em></p><p>These should be tested before treatment is started, then at regular intervals. Reduction in sodium levels can be initially asymptomatic and regular testing is therefore essential. Testing should be more frequent in elderly and cirrhotic patients (see sections 4.8 and 4.9). Any diuretic treatment may cause hyponatraemia, sometimes with very serious consequences. Hyponatraemia with hypovolaemia may be responsible of dehydration and orthostatic hypotension. Concomitant loss of chloride ions may lead to secondary compensatory metabolic alkalosis: the incidence and degree of this effect are slight.</p><p>&nbsp;</p><p><em>Potassium levels</em></p><p>Potassium depletion with hypokalaemia is a major risk with thiazide diuretics and thiazide-related diuretics. Hypokalaemia may cause muscle disorders. Cases of Rhabdomyolysis have been reported, mainly in the context of severe hypokalaemia. The risk of onset of lowered potassium levels (&lt;&nbsp;3.4&nbsp;mmol/l) should be prevented in some high risk populations such as elderly and/or malnourished subjects, whether or not they are taking multiple medications, cirrhotic patients with oedema and ascites, coronary patients and patients with heart failure.</p><p>In such cases hypokalaemia increases the cardiac toxicity of cardiac glycosides and the risk of rhythm disorders.</p><p>Subjects presenting with a long QT interval are also at risk, whether the origin is congenital or iatrogenic. Hypokalaemia, as with bradycardia, acts as a factor which favours the onset of severe rhythm disorders, in particular torsades de pointes, which may be fatal.</p><p>In all cases more frequent testing of potassium levels is necessary. The first measurement of plasma potassium levels should be carried out during the first week following the start of treatment.</p><p>If low potassium levels are detected, correction is required. Hypokalaemia found in association with low serum magnesium concentration can be refractory to treatment unless serum magnesium is corrected.</p><p>&nbsp;</p><p><em>Calcium levels</em></p><p>Thiazide diuretics and thiazide-related diuretics may reduce urinary excretion of calcium and cause a mild and transient increase in plasma calcium levels. Markedly raised levels of calcium may be related to undiagnosed hyperparathyroidism. In such cases the treatment should be stopped before investigating the parathyroid function.</p><p>&nbsp;</p><p>&nbsp;</p><p>Plasma magnesium:</p><p>Thiazides and related diuretics including indapamide have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia (see section 4.5 and 4.8).</p><p>&nbsp;</p><p><em>Blood glucose</em></p><p>Monitoring of blood glucose is important in diabetic patients, particularly when potassium levels are low.</p><p>&nbsp;</p><p><em>Uric acid</em></p><p>Tendency to gout attacks may be increased in hyperuricaemic patients.</p><p>&nbsp;</p><p><em>Renal function and diuretics</em></p><p>Thiazide diuretics and thiazide-related diuretics are only fully effective when renal function is normal or only slightly impaired (creatinine levels lower than approximately 25 mg/l, i.e. 220&nbsp;&micro;mol/l for an adult).</p><p>In the elderly the value of plasma creatinine levels should be adjusted to take account of the age, weight and sex of the patient, according to the Cockroft formula:</p><p>cl<sub>cr</sub> = (140 - age) x body weight / 0.814 x plasma creatinine level</p><p>with: age expressed in years</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; body weight in kg</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plasma creatinine level in micromol/l</p><p>This formula is suitable for an elderly male and should be adapted for women by multiplying the result by 0.85.</p><p>Hypovolaemia, resulting from the loss of water and sodium caused by the diuretic at the start of treatment, causes a reduction in glomerular filtration. It may result in an increase in blood urea and creatinine levels. This transitory functional renal insufficiency is of no adverse consequence in patients with normal renal function but may however worsen a pre-existing renal impairment.</p><p>&nbsp;</p><p><em>Athletes</em></p><p>Athletes should note that this product contains an active substance which may cause a positive reaction in doping tests.</p><p>&nbsp;</p><p><em>Choroidal effusion, acute myopia and secondary angle-closure glaucoma</em></p><p>Sulfonamide, or sulfonamide derivative, drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Common to perindopril and indapamide</u></em></p><p>&nbsp;</p><p><strong><em><u>Concomitant use not recommended:</u></em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Lithium:</strong> Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE&nbsp;inhibitors.&nbsp; Use of perindopril combined with indapamide with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p>&nbsp;</p><p><strong><em>Concomitant use</em></strong><strong> <em>which requires special care:</em></strong></p><p>-&nbsp;&nbsp;&nbsp; <strong>Baclofen:</strong> Increased antihypertensive effect. Monitor blood pressure and adapt antihypertensive dosage if necessary.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Non-steroidal anti-inflammatory medicinal products (NSAIDs) (including acetylsalicylic acid &ge; 3g/day) : </strong>When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>&nbsp;</p><p><strong><em><u>Concomitant use</u></em></strong><strong><u> <em>which requires some care:</em></u></strong></p><p><strong>-&nbsp;&nbsp;&nbsp; Imipramine-like antidepressants (tricyclics), neuroleptics: </strong>Increased antihypertensive effect and increased risk of orthostatic hypotension (additive effect).</p><p>&nbsp;</p><p><em><u>Linked</u></em><em><u> to perindopril</u></em></p><p><em><u>&nbsp;</u></em></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><strong><em><u>Drugs increasing the risk of angioedema </u></em></strong></p><p>Concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see section 4.3 and 4.4). Sacubitril/valsartan must not be started until 36 hours after taking the last dose of perindopril therapy. Perindopril therapy must not be started until 36 hours after the last dose of sacubitril/valsartan (see sections 4.3 and 4.4).</p><p>Concomitant use of ACE inhibitors with racecadotril, mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus) and gliptins (e.g. linagliptin, saxagliptin, sitagliptin, vildagliptin) may lead to an increased risk for angioedema (see section 4.4).</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><strong><em><u>Drugs inducing hyperkalaemia</u></em></strong></p><p>Although serum potassium usually remains within normal limits, hyperkalaemia may occur in some patients treated with of Preterax 2.5mg/0.625mg. Some drugs or therapeutic classes may increase the occurrence of hyperkalaemia: aliskiren, potassium salts, potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), ACE inhibitors, angiotensin-II receptor antagonists, NSAIDs, heparins, immunosuppressant agents such as ciclosporin or tacrolimus, trimethoprim and cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like amiloride. The combination of these drugs increases the risk of hyperkalaemia. Therefore, the combination of Preterax 2.5mg/0.625mg with the above-mentioned drugs is not recommended. If concomitant use is indicated, they should be used with caution and with frequent monitoring of serum potassium.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Concomitant use contra-indicated (see section 4.3):</u></em></strong></p><p><strong>Aliskiren:</strong> In diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase.</p><p><strong>Extracorporeal treatments: </strong>Extracorporeal treatments leading to contact of blood with negatively charged surfaces such as dialysis or haemofiltration with certain high-flux membranes (e.g. polyacrylonitril membranes) and low density lipoprotein apheresis with dextran sulphate due to increased risk of severe anaphylactoid reactions (see section 4.3). If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p><em>&nbsp;</em></p><p><strong><em><u>Concomitant use not recommended:</u></em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Aliskiren:</strong> In patients other than diabetic or impaired renal patients, risk of hyperkalaemia, worsening of renal function and cardiovascular morbidity and mortality increase (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Concomitant therapy with ACE inhibitor and angiotensin-receptor blocker:</strong> It has been reported in the literature that in patients with established atherosclerotic disease, heart failure, or with diabetes with end organ damage, concomitant therapy with an ACE inhibitor and an angiotensin-receptor blocker is associated with a higher frequency of hypotension, syncope, hyperkalaemia, and worsening renal function (including acute renal failure) as compared to use of a single renin-angiotensin-aldosterone system agent. Dual blockade (e.g, by combining an ACE-inhibitor with an angiotensin II receptor antagonist) should be limited to individually defined cases with close monitoring of renal function, potassium levels, and blood pressure (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp; <strong>Estramustine:</strong> Risk of increased adverse effects such as angioneurotic oedema (angioedema).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Potassium-sparing diuretics ( e.g. triamterene, amiloride&hellip; ), potassium (salts):</strong> Hyperkalaemia (potentially lethal), especially in conjunction with renal impairment (additive hyperkalaemic effects). The combination of perindopril with the above-mentioned drugs is not recommended (see section 4.4). If concomitant use is nonetheless indicated, they should be used with caution and with frequent monitoring of serum potassium. For use of spironolactone in heart failure, see section &ldquo;Concomitant use which requires special care&rdquo;.</p><p>&nbsp;</p><p><strong><em><u>Concomitant use</u></em></strong><strong><u> <em>which requires special care:</em></u></strong></p><p>-&nbsp;&nbsp;&nbsp; <strong>Antidiabetic agents (insulin, oral hypoglycaemic agents ):</strong><strong> </strong>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Non-potassium-sparing diuretics</strong><strong>:</strong> Patients on diuretics, and especially those who are volume and/or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor. The possibility of hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake prior to initiating therapy with low and progressive doses of perindopril.</p><p><em>In arterial hypertension,</em> when prior diuretic therapy can have caused salt/volume depletion, either the diuretic must be discontinued before initiating the ACE inhibitor, in which case a non-potassium-sparing diuretic can be thereafter reintroduced or the ACE inhibitor must be initiated with a low dosage and progressively increased.</p><p><em>In diuretic-treated congestive heart failure,</em> the ACE inhibitor should be initiated at a very low dosage, possibly after reducing the dosage of the associated non-potassium-sparing diuretic.</p><p>In all cases, renal function (creatinine levels) must be monitored during the first few weeks of ACE inhibitor therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Potassium-sparing diuretics (eplerenone, spironolactone): </strong>With eplerenone or spironolactone at doses between 12.5 mg to 50 mg per day and with low doses of ACE inhibitors:</p><p>In the treatment of class II-IV heart failure (NYHA) with an ejection fraction &lt;40%, and previously treated with ACE inhibitors and loop diuretics, risk of hyperkalaemia, potentially lethal, especially in case of non-observance of the prescription recommendations about this combination.</p><p>Before initiating the combination, check the absence of hyperkalaemia and renal impairment.</p><p>Close monitoring of the kalaemia and creatininemia is recommended in the first month of the treatment once a week at the beginning and, monthly thereafter.</p><p>&nbsp;</p><p><strong><em><u>Concomitant use</u></em></strong><strong><u> <em>which requires some care:</em></u></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Antihypertensive agents and vasodilatators:</strong> Concomitant use of these agents may increase the hypotensive effects of perindopril. Concomitant use with nitroglycerin and other nitrates, or other vasodilatators, may further reduce blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Allopurinol, cytostatic or immunosuppressive agents, systemic corticosteroids or procainamide:</strong> Concomitant administration with ACE inhibitors may lead to an increased risk for leucopenia (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp; <strong>Anaesthetic drugs:</strong> ACE inhibitors may enhance the hypotensive effects of certain anaesthetic drugs (see section 4.4).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Sympathomimetics:</strong> Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gold:</strong> Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including perindopril.</p><p>&nbsp;</p><p><em><u>Linked</u></em><em><u> to indapamide</u></em></p><p>&nbsp;</p><p><strong><em><u>Concomitant use</u></em></strong><strong><em><u> which requires special care:</u></em></strong></p><p>-&nbsp;&nbsp;&nbsp; <strong>Torsades de pointes inducing drugs:</strong> Due to the risk of hypokalaemia, indapamide should be administered with caution when associated with medicinal products that induced torsades de pointes such as but not limited to: class Ia antiarrhythmic agents (e.g. quinidine, hydroquinidine, disopyramide); class III antiarrhythmic agents (e.g. amiodarone, dofetilide, ibutilide, bretylium,&nbsp; sotalol); some antipsychotics <s>neuroleptics</s></p><p>&nbsp;&nbsp;&nbsp;&nbsp; Phenothiazine (e.g. chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine), benzamides (e.g. amisulpride, sulpiride, sultopride, tiapride), butyrophenones (e.g. droperidol, haloperidol), other <s>neuroleptics</s> antipsychotics (e.g. pimozide); other substances (e.g. bepridil, cisapride, diphemanil, <s>IV</s> erythromycin IV, halofantrine, mizolastine, moxifloxacin, pentamidine, sparfloxacin, <s>IV</s> vincamine IV, methadone, astemizole, terfenadine). Prevention of low potassium levels and correction if necessary: monitoring of the QT interval.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Potassium-lowering drugs: </strong>amphotericin B (IV route), glucocorticoids and mineralocorticoids (systemic route), tetracosactide, stimulant laxatives: Increased risk of low potassium levels (additive effect). Monitoring of potassium levels, and correction if necessary ; particular consideration required in cases of treatment with digitalis. Non stimulant laxatives should be used.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Digitalis preparations:</strong> Hypokalaemia and/or hypomagnesaemia predispose to the toxic effects of digitalis. Monitoring of plasma potassium, magnesium and ECG is recommended and, if necessary, adjusting the treatment. <strong>Allopurinol: </strong>concomitant treatment with indapamide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p>&nbsp;</p><p><strong><em><u>Concomitant use</u></em></strong><strong><em><u> which requires some care:</u></em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Potassium-sparing diuretics (amiloride, spironolactone, triamterene): </strong>Whilst rational combinations are useful in some patients, hypokalaemia&nbsp; or hyperkalaemia (particularly in patients with renal failure or diabetes) may still occur. Plasma potassium and ECG should be monitored and, if necessary, treatment reviewed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metformin: </strong>Lactic acidosis due to metformin caused by possible functional renal insufficiency linked to diuretics and in particular to loop diuretics. Do not use metformin when plasma creatinine levels exceed 15&nbsp;mg/l (135&nbsp;micromol/l) in men and 12&nbsp;mg/l (110&nbsp;micromol/l) in women.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Iodinated contrast media:</strong><strong> </strong>In cases of dehydration caused by diuretics, there is an increased risk of acute renal insufficiency, particularly when high doses of iodinated contrast media are used. Rehydration should be carried out before the iodinated compound is administered.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Calcium (salts): </strong>Risk of increased levels of calcium due to reduced elimination of calcium in the urine.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Ciclosporin, </strong><strong>tacrolimus</strong><strong>:</strong><strong> </strong>Risk of increased creatinine levels with no change in circulating levels of ciclosporin, even when there is no salt and water depletion.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Corticosteroids, tetracosactide (systemic route):</strong> Reduction in antihypertensive effect (salt and water retention due to corticosteroids).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the effects of the individual components in this combination product on pregnancy and lactation, Preterax 2.5mg/0.625mg is not recommended during the first trimester of pregnancy. Preterax 2.5mg/0.625mg is contraindicated during the second and third trimesters of pregnancy.</p><p>Preterax 2.5mg/0.625mg is not recommended during lactation. A decision should therefore be made whether to discontinue nursing or to discontinue Preterax 2.5mg/0.625mg taking account the importance of this therapy for the mother.</p><p>&nbsp;</p><p><strong><u>Pregnancy</u></strong></p><p>&nbsp;</p><p><em><u>Linked to perindopril</u></em></p><p><s>&nbsp;</s></p><p><strong>The use of ACE inhibitors</strong><strong> </strong><strong>is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors</strong><strong> </strong><strong>is contra-indicated during the </strong><strong>second and third </strong><strong>trimesters of pregnancy (see sections 4.3 and 4.4).</strong></p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive ; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em><u>Linked to indapamide</u></em></p><p>&nbsp;</p><p>There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of indapamide in pregnant women. Prolonged exposure to thiazide during the third trimester of pregnancy can reduce maternal plasma volume as well as uteroplacental blood flow, which may cause a feto-placental ischemia and growth retardation.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p><strong>&nbsp;</strong></p><p>As a precautionary measure, it is preferable to avoid the use of Indapamide during pregnancy.</p><p><strong>&nbsp;</strong></p><p><strong><u>Breast-feeding</u></strong></p><p>&nbsp;</p><p>Preterax 2.5mg/0.625mg is not recommended during lactation.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Linked to perindopril</u></em></p><p>&nbsp;</p><p>Because no information is available regarding the use of perindopril&nbsp; during breast-feeding, perindopril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p>&nbsp;</p><p><em><u>Linked to indapamide</u></em></p><p>&nbsp;</p><p>There is insufficient information on the excretion of indapamide/metabolites in human milk. Hypersensitivity to sulfonamide-derived drugs and hypokalaemia&nbsp; might occur. A risk to the newborns/infants cannot be excluded.</p><p>Indapamide is closely related to thiazide diuretics which have been associated, during breast-feeding, with decrease or even suppression of milk lactation.</p><p>&nbsp;</p><p>Indapamide is not recommended during breast-feeding.</p><p>&nbsp;</p><p><strong><u>Fertility</u></strong></p><p>&nbsp;</p><p><em><u>Common to perindopril and indapamide</u></em></p><p>&nbsp;</p><p>Reproductive toxicity studies showed no effect on fertility in female and male rats (see section 5.3). No effects on human fertility are anticipated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Linked to perindopril, indapamide and Preterax 2.5mg/0.625mg</u></em></p><p>&nbsp;</p><p>The two active substances, individually or combined in Preterax 2.5mg/0.625mg, have no influence on the ability to drive and use machines<strong><em> </em></strong>but individual reactions related to low blood pressure may occur in some patients, particularly at the start of treatment or in combination with another antihypertensive medication.</p><p>As a result the ability to drive or operate machinery may be impaired.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a. Summary of safety profile</p><p>&nbsp;</p><p>The administration of perindopril inhibits the renin-angiotensin-aldosterone axis and tends to reduce the potassium loss caused by indapamide.</p><p>Two percent of the patients on treatment with Preterax 2.5mg/0.625mg experience hypokalaemia (potassium level &lt; 3.4 mmol/l).</p><p>&nbsp;</p><p>The most commonly reported adverse reactions observed are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with perindopril : dizziness, headache, paraesthesia, dysgeusia, visual impairment, vertigo, tinnitus, hypotension, cough, dyspnoea, abdominal pain, constipation, dyspepsia, diarrhoea, nausea, vomiting, pruritus, rash, muscle spasms and asthenia.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; with indapamide : hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions and maculopapular rashes..</p><p>&nbsp;</p><p>b. Tabulated list of adverse reactions</p><p>&nbsp;</p><p>The following undesirable effects have been&nbsp; observed during clinical trials and/or post-marketing use and ranked under the following frequency:</p><p>Very common (&sup3;1/10); common (&sup3;1/100, &lt;1/10); uncommon (&sup3;1/1000, &lt;1/100); rare (&sup3;1/10000, &lt;1/1000), very rare (&lt;1/10000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2">&nbsp;<p><strong>MedDRA</strong></p><p><strong>System Organ Class</strong></p></td><td rowspan="2"><p><strong>Undesirable Effects</strong></p></td><td colspan="2"><p><strong>Frequency</strong></p></td></tr><tr><td><p><strong>Perindopril</strong></p></td><td><p><strong>Indapamide</strong></p></td></tr><tr><td><p><strong>Infections and infestations</strong></p></td><td><p>Rhinitis</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p><strong>Endocrine disorders</strong></p></td><td><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td><td><p>Rare</p></td><td><p>-</p></td></tr><tr><td rowspan="8"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td><p>Eosinophilia</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr><tr><td><p>Agranulocytosis (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Aplastic anaemia</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Pancytopenia</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Leukopenia</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Neutropenia (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Haemolytic anaemia</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Thrombocytopenia (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p><strong>Immune system disorders</strong></p></td><td><p>Hypersensitivity (reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions)</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td rowspan="7"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td><p>Hypoglycaemia (see sections 4.4 and 4.5)</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr><tr><td><p>Hyperkalaemia, reversible on discontinuation (see section 4.4)</p></td><td><p>Uncommon*</p><p>&nbsp;</p></td><td><p>-</p></td></tr><tr><td><p>Hyponatraemia (see section 4.4)</p></td><td><p>Uncommon*</p></td><td><p>Not known</p></td></tr><tr><td><p>Hypochloraemia</p></td><td><p>-</p></td><td><p>Rare</p></td></tr><tr><td><p>Hypomagnesaemia</p></td><td><p>-</p></td><td><p>Rare</p></td></tr><tr><td><p>Hypercalcaemia</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>&nbsp;Hypokalemia</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td rowspan="4"><p><strong>Psychiatric Disorders</strong></p></td><td><p>Mood altered</p></td><td><p>Uncommon</p></td><td><p>-</p></td></tr><tr><td><p>Depression</p></td><td><p>Uncommon*</p></td><td><p>-&nbsp;&nbsp;&nbsp; &nbsp;</p></td></tr><tr><td><p>Sleep disorder</p></td><td><p>Uncommon</p></td><td><p>-</p></td></tr><tr><td><p>Confusion</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td rowspan="8"><p><strong>Nervous System Disorders</strong></p></td><td><p>&nbsp;Dizziness</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Headache</p></td><td><p>Common</p></td><td><p>Rare</p></td></tr><tr><td><p>Paraesthesia</p></td><td><p>Common</p></td><td><p>Rare</p></td></tr><tr><td><p>Dysgeusia</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Somnolence</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr><tr><td><p>Syncope</p></td><td><p>Uncommon*</p></td><td><p>Not known</p></td></tr><tr><td><p>Stroke possibly secondary to excessive hypotension in high-risk patients (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Possibility of onset of hepatic encephalopathy in case of hepatic insufficiency (see sections 4.3 and 4.4)</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td rowspan="5"><p><strong>Eye Disorders</strong></p></td><td><p>Visual impairment</p></td><td><p>Common</p></td><td><p>Not known</p></td></tr><tr><td><p>Myopia (see section 4.4)</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p>Acute angle-closure glaucoma</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p>Choroidal effusion</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p>Vision blurred</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td rowspan="2"><p><strong>Ear and Labyrinth Disorders</strong></p></td><td><p>Vertigo</p></td><td><p>Common</p></td><td><p>Rare</p></td></tr><tr><td><p>Tinnitus</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td rowspan="6"><p><strong>Cardiac Disorders</strong></p></td><td><p>Palpitations</p></td><td><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Tachycardia</p></td><td><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Angina pectoris (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Arrhythmia (including bradycardia, ventricular tachycardia, atrial fibrillation)</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td><p>Myocardial infarction possibly secondary to excessive hypotension in high risk patients (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Torsade de pointes (potentially fatal) (see sections 4.4 and 4.5)</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td rowspan="4"><p><strong>Vascular Disorders</strong></p></td><td><p>Hypotension&nbsp;&nbsp; (and effects related to hypotension) (see section 4.4)</p></td><td><p>Common</p></td><td><p>Very rare</p></td></tr><tr><td><p>Vasculitis</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr><tr><td><p>Flushing</p></td><td><p>Rare*</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Raynaud&rsquo;s phenomenon</p></td><td><p>Not known</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="5"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td><p>Cough (see section 4.4)</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Dyspnoea</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Bronchospasm</p></td><td><p>Uncommon</p></td><td><p>-</p></td></tr><tr><td><p>Eosinophilic pneumonia</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="8"><p><strong>Gastrointestinal Disorders</strong></p></td><td><p>Abdominal pain</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Constipation</p></td><td><p>Common</p></td><td><p>Rare</p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Nausea</p></td><td><p>Common</p></td><td><p>Rare</p></td></tr><tr><td><p>Vomiting</p></td><td><p>Common</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Dry mouth</p></td><td><p>Uncommon</p></td><td><p>Rare</p></td></tr><tr><td><p>Pancreatitis</p></td><td><p>Very rare</p></td><td><p>Very rare</p></td></tr><tr><td rowspan="2"><p><strong>Hepatobiliary Disorders</strong></p></td><td><p>Hepatitis&nbsp; (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>Not known</p></td></tr><tr><td><p>Hepatic function abnormal</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td rowspan="13"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td><p>Pruritus</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Rash</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Rash maculo-papular</p></td><td><p>-</p></td><td><p>Common</p></td></tr><tr><td><p>Urticaria (see section 4.4)</p></td><td><p>Uncommon</p></td><td><p>Very rare</p></td></tr><tr><td><p>Angioedema&nbsp; (see section 4.4)</p></td><td><p>Uncommon</p></td><td><p>Very rare</p></td></tr><tr><td><p>Purpura</p></td><td><p>-</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Hyperhidrosis</p></td><td><p>Uncommon</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Photosensitivity reaction</p></td><td><p>Uncommon*</p></td><td><p>Not known</p></td></tr><tr><td><p>Pemphigoid</p></td><td><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Psoriasis aggravation</p></td><td style="vertical-align:top"><p>Rare*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Erythema multiforme</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Toxic epidermal necrolysis</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td><p>Stevens Johnson syndrome</p></td><td><p>-</p></td><td><p>Very rare</p></td></tr><tr><td rowspan="6"><p><strong>Musculoskeletal and Connective Tissue Disorders</strong></p></td><td><p>Muscle spasms <s>cramps</s></p></td><td><p>Common</p></td><td><p>Not known</p></td></tr><tr><td><p>Possible worsening of pre-existing acute disseminated lupus erythematosus</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p>Arthralgia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td><p>Muscular weakness</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td><p>Rhabdomyolysis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="3"><p><strong>Renal and Urinary Disorders</strong></p></td><td><p>Renal failure</p></td><td><p>Uncommon</p></td><td><p>-</p></td></tr><tr><td><p>Anuria/oliguria</p></td><td><p>Rare*</p></td><td><p>-</p></td></tr><tr><td><p>Acute renal failure</p></td><td><p>Rare</p></td><td><p>Very rare</p></td></tr><tr><td><p><strong>Reproductive System and Breast disorders</strong></p></td><td><p>Erectile dysfunction</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="6"><p><strong>General Disorders and Administration Site Conditions</strong></p></td><td><p>Asthenia</p></td><td><p>Common</p></td><td><p>-</p></td></tr><tr><td><p>Chest pain</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr><tr><td><p>Malaise</p></td><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Pyrexia</p></td><td style="vertical-align:top"><p>Uncommon*</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td><p>Fatigue</p></td><td><p>-</p></td><td><p>Rare</p></td></tr><tr><td rowspan="8"><p><strong>Investigations</strong></p></td><td><p>Blood urea increased.</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr><tr><td><p>Blood creatinine increased.</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr><tr><td><p>Blood bilirubin increased</p></td><td><p>Rare</p></td><td><p>-</p></td></tr><tr><td><p>Hepatic enzyme increased</p></td><td><p>Rare</p></td><td><p>Not known</p></td></tr><tr><td><p>Haemoglobin decreased and haematocrit decreased (see section 4.4)</p></td><td><p>Very rare</p></td><td><p>-</p></td></tr><tr><td><p>Blood glucose increased</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p>Blood uric acid increased</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p>Electrocardiogram QT prolonged (see sections 4.4 and 4.5)</p></td><td><p>-</p></td><td><p>Not known</p></td></tr><tr><td><p><strong>Injury, Poisoning and Procedural Complications</strong></p></td><td><p>Fall</p></td><td><p>Uncommon*</p></td><td><p>-</p></td></tr></tbody></table><p><em>* Frequency calculated from clinical trials for adverse events detected from spontaneous report.</em></p><p>Cases of SIADH have been reported with other ACE inhibitors. SIADH can be considered as a very rare but possible complication associated with ACE inhibitor therapy including perindopril.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>- National Pharmacovigilance Center (NPC)</em></strong></p><p><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Fax: +966-11-205-7662</em></strong></p><p><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - SFDA call Center 19999</em></strong></p><p><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Toll free phone: 8002490000</em></strong></p><p><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - E-mail: npc.drug@sfda.gov.sa</em></strong></p><p><strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Website: www.sfda.gov.sa/npc</em></strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; <strong><em>Other GCC states:</em></strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- Please contact the relevant competent authority</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>The most likely adverse reaction in cases of overdose is hypotension, sometimes associated with nausea, vomiting, cramps, dizziness, sleepiness, mental confusion, oliguria which may progress to anuria (due to hypovolaemia). Salt and water disturbances (low sodium levels, low potassium levels) may occur.</p><p>&nbsp;</p><p><u>Management</u></p><p>The first measures to be taken consist of rapidly eliminating the product(s) ingested by gastric lavage and/or administration of activated charcoal, then restoring fluid and electrolyte balance in a specialised centre until they return to normal.</p><p>If marked hypotension occurs, this can be treated by placing the patient in a supine position with the head lowered. If necessary an intravenous<strong><em> </em></strong>infusion of isotonic saline may be given, or any other method of volaemic expansion may be used.</p><p>Perindoprilat, the active form of perindopril, can be dialysed (see section 5.2).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: perindopril and diuretics, ATC code: C09BA04</p><p>Preterax 2.5mg/0.625mg is a combination of perindopril arginine salt, an angiotensin converting enzyme inhibitor, and indapamide, a chlorosulphamoyl diuretic. Its pharmacological properties are derived from those of each of the components taken separately, in addition to those due to the additive synergic action of the two products when combined.</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>&nbsp;</p><p><em><u>Linked to Preterax 2.5mg/0.625mg</u></em></p><p>&nbsp;</p><p>Preterax 2.5mg/0.625mg produces an additive synergy of the antihypertensive effects of the two components.</p><p>&nbsp;</p><p><em><u>Linked to perindopril</u></em></p><p>&nbsp;</p><p>Perindopril is an inhibitor of the angiotensin converting enzyme (ACE inhibitor) which converts angiotensin I to angiotensin II, a vasoconstricting substance ; in addition the enzyme stimulates the secretion of aldosterone by the adrenal cortex and stimulates the degradation of bradykinin, a vasodilatory substance, into inactive heptapeptides.</p><p>This results in:</p><p>-&nbsp;&nbsp; a reduction in aldosterone secretion,</p><p>-&nbsp;&nbsp; an increase in plasma renin activity, since aldosterone no longer exercises negative feedback,</p><p>-&nbsp;&nbsp; a reduction in total peripheral resistance with a preferential action on the vascular bed in muscle and the kidney, with no accompanying salt and water retention or reflex tachycardia, with chronic treatment.</p><p>&nbsp;</p><p>The antihypertensive action of perindopril also occurs in patients with low or normal renin concentrations.</p><p>&nbsp;</p><p>Perindopril acts through its active metabolite, perindoprilat. The other metabolites are inactive.</p><p>Perindopril reduces the work of the heart:</p><p>-&nbsp;&nbsp; by a vasodilatory effect on veins, probably caused by changes in the metabolism of prostaglandins: reduction in pre-load,</p><p>-&nbsp;&nbsp; by reduction of the total peripheral resistance: reduction in afterload.</p><p>&nbsp;</p><p>Studies carried out on patients with cardiac insufficiency have shown:</p><p>-&nbsp;&nbsp; a reduction in left and right ventricular filling pressures,</p><p>-&nbsp;&nbsp; a reduction in total peripheral vascular resistance,</p><p>-&nbsp;&nbsp; an increase in cardiac output and an improvement in the cardiac index,</p><p>-&nbsp;&nbsp; an increase in regional blood flow in muscle.</p><p>Exercise test results also showed improvement.</p><p>&nbsp;</p><p><em><u>Linked to indapamide</u></em></p><p>&nbsp;</p><p>Indapamide is a sulphonamide derivative with an indole ring, pharmacologically related to the thiazide group of diuretics. Indapamide inhibits the reabsorption of sodium in the cortical dilution segment. It increases the urinary excretion of sodium and chlorides and, to a lesser extent, the excretion of potassium and magnesium, thereby increasing urine output and having an antihypertensive action.</p><p><strong>&nbsp;</strong></p><p><em><u>Pharmacodynamic effects</u></em></p><p><em><u>&nbsp;</u></em></p><p><em><u>&nbsp;</u></em></p><p><em><u>&nbsp;</u></em></p><p><em><u>Linked to Preterax 2.5mg/0.625mg</u></em></p><p>&nbsp;</p><p>In hypertensive patients regardless of age, Preterax 2.5mg/0.625mg exerts a dose-dependent antihypertensive effect on diastolic and systolic arterial pressure whilst supine or standing. This antihypertensive effect lasts for 24 hours. The reduction in blood pressure is obtained in less than one month without tachyphylaxis&nbsp;; stopping treatment has no rebound effect. During clinical trials, the concomitant administration of perindopril and indapamide produced antihypertensive effects of a synergic nature in relation to each of the products administered alone.</p><p>The effect of the low-dose combination Preterax 2.5mg/0.625mg on cardiovascular morbidity and mortality has not been studied.</p><p>&nbsp;</p><p>PICXEL, a multicenter, randomised, double blind active controlled study has assessed on echocardiography the effect of perindopril/indapamide combination on LVH versus enalapril monotherapy.</p><p>In PICXEL, hypertensive patients with LVH (defined as left ventricular mass index (LVMI) &gt; 120 g/m<sup>2</sup> in male and &gt; 100 g/m<sup>2</sup> in female) were randomised either to perindopril tert-butylamine 2 mg (equivalent to 2.5 mg perindopril arginine)/indapamide 0.625 mg or to enalapril 10 mg once a day for a one-year treatment. The dose was adapted according to blood pressure control, up to perindopril tert-butylamine 8 mg (equivalent to 10 mg perindopril arginine) and indapamide 2.5 mg or enalapril 40 mg once a day. Only 34% of the subjects remained treated with perindopril tert-butylamine 2 mg (equivalent to 2.5 mg perindopril arginine)/indapamide 0.625mg (versus 20% with Enalapril 10mg).</p><p>At the end of treatment, LVMI had decreased significantly more in the perindopril/indapamide group (-10.1 g/m&sup2;) than in the enalapril group (-1.1 g/m&sup2;) in the all randomised patients population. The between group difference in LVMI change was -8.3 (95% CI (-11.5,-5.0), p &lt; 0.0001).</p><p>A better effect on LVMI was reached with higher perindopril/indapamide doses than those licensed for&nbsp; Preterax 2.5mg/0.625mg and&nbsp; Bipreterax 5mg/1.25mg.</p><p>&nbsp;</p><p>Regarding blood pressure, the estimated mean between-group differences in the randomised population were -5.8 mmHg (95% CI (-7.9, -3.7), p &lt; 0.0001) for systolic blood pressure and -2.3 mmHg (95% CI (-3.6,-0.9), p = 0.0004) for diastolic blood pressure respectively, in favour of the perindopril/indapamide group.</p><p>&nbsp;</p><p><em><u>Linked to perindopril</u></em></p><p>&nbsp;</p><p>Perindopril is active in all grades of hypertension: mild to moderate or severe. A reduction in systolic and diastolic arterial pressure is observed in the lying and standing position.</p><p>The antihypertensive activity after a single dose is maximal at between 4 and 6 hours and is maintained over 24 hours.</p><p>There is a high degree of residual blocking of angiotensin converting enzyme at 24 hours, approximately&nbsp;80%.</p><p>In patients who respond, normalised blood pressure is reached after one month and is maintained without tachyphylaxis.</p><p>Withdrawal of treatment has no rebound effect on hypertension.</p><p>Perindopril has vasodilatory properties and restores elasticity of the main arterial trunks, corrects histomorphometric changes in resistance arteries and produces a reduction in left ventricular hypertrophy.</p><p>If necessary, the addition of a thiazide diuretic leads to an additive synergy.</p><p>The combination of an angiotensin converting enzyme inhibitor with a thiazide diuretic decreases the hypokalaemia risk associated with the diuretic alone.</p><p>&nbsp;</p><p><em><u>Linked to indapamide</u></em></p><p>&nbsp;</p><p>Indapamide, as monotherapy, has an antihypertensive effect which lasts for 24&nbsp;hours. This effect occurs at doses at which the diuretic properties are minimal.</p><p>Its antihypertensive action is proportional to an improvement in arterial compliance and a reduction in total and arteriolar peripheral vascular resistance.</p><p>Indapamide reduces left ventricular hypertrophy.</p><p>When a dose of thiazide diuretic and thiazide-related diuretics is exceeded, the antihypertensive effect reaches a plateau, whereas the adverse effects continue to increase. If the treatment is ineffective, the dose should not be increased.</p><p>Furthermore, it has been shown that in the short-term, mid-term and long-term in hypertensive patients, indapamide:</p><p>-&nbsp;&nbsp; has no effect on lipid metabolism: triglycerides, LDL-cholesterol and HDL-cholesterol,</p><p>-&nbsp;&nbsp; has no effect on carbohydrate metabolism, even in diabetic hypertensive patients.</p><p>&nbsp;</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) clinical trial data:</em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed.</p><p>Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. CV death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p><em>Paediatric use</em></p><p>No data are available with Preterax in children.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Linked to Preterax 2.5mg/0.625mg</u></em></p><p>&nbsp;</p><p>The co-administration of perindopril and indapamide does not change their pharmacokinetic properties by comparison to separate administration.</p><p>&nbsp;</p><p><em><u>Linked to perindopril</u></em></p><p>&nbsp;</p><p><u>Absorption and bioavailability</u></p><p>After oral administration, the absorption of perindopril is rapid and the peak concentration is achieved<strong><em> </em></strong>within 1 hour. The plasma half-life of perindopril is equal to 1 hour.</p><p>As ingestion of food decreases conversion to perindoprilat, hence bioavailability, perindopril arginine<strong><em> </em></strong>should be administered orally in a single daily dose in the morning before a meal.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The volume of distribution is approximately 0.2 l/kg for unbound perindoprilat. Protein binding of perindoprilat to plasma proteins is 20%, principally to angiotensin converting enzyme, but is concentration-dependent.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Perindopril is a prodrug. Twenty seven percent of the administered perindopril dose reaches the bloodstream as the active metabolite perindoprilat. In addition to active perindoprilat, perindopril yields five metabolites, all inactive. The peak plasma concentration of perindoprilat is achieved within 3 to 4 hours.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Perindoprilat is eliminated in the urine and the terminal half-life of the unbound fraction is approximately 17 hours, resulting in steady-state within 4 days.</p><p><u>&nbsp;</u></p><p><u>Linearity/non-linearity</u></p><p>It has been demonstrated a linear relationship between the dose of perindopril and its plasma exposure.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly:</em></p><p>Elimination of perindoprilat is decreased in the elderly, and also in patients with heart or renal failure.</p><p>&nbsp;</p><p><em>Renal impairment</em>:</p><p>Dosage adjustment in renal insufficiency is desirable depending on the degree of impairment (creatinine clearance).</p><p>&nbsp;</p><p><em>In case of dialysis</em>:</p><p>Dialysis clearance of perindoprilat is equal to 70 ml/min.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Cirrhosis</em>:</p><p>Perindopril kinetics are modified in patients with cirrhosis: hepatic clearance of the parent molecule is reduced by half. However, the quantity of perindoprilat formed is not reduced and therefore no dosage adjustment is required (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em><u>Linked to indapamide</u></em></p><p>&nbsp;</p><p><u>Absorption</u></p><p>Indapamide is rapidly and completely absorbed from the digestive tract.</p><p>The peak plasma level is reached in humans approximately one hour after oral administration of the product.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Plasma protein binding is 79 %.</p><p>&nbsp;</p><p><u>Biotransformation and Elimination</u></p><p>The elimination half-life is between 14 and 24 hours (average 18 hours). Repeated administration does not produce accumulation. Elimination is mainly in the urine (70 % of the dose) and faeces (22&nbsp;%) in the form of inactive metabolites.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal</em><em> impairment</em>:</p><p>The pharmacokinetics are unchanged in patients with renal insufficiency.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preterax 2.5mg/0.625mg has slightly increased toxicity than that of its components. Renal manifestations do not seem to be potentiated in the rat. However, the combination produces gastro-intestinal toxicity in the dog and the toxic effects on the mother seem to be increased in the rat (compared to perindopril).</p><p>Nonetheless, these adverse effects are shown at dose levels corresponding to a very marked safety margin by comparison to the therapeutic doses used.</p><p>Preclinical studies performed separately with perindopril and indapamide did not show genotoxic or carcinogenic potential. Reproduction toxicology studies showed no embryotoxicity or teratogenicity and fertility was not impaired.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Core:</em></strong></p><p>Lactose monohydrate</p><p>Magnesium stearate (E470B)</p><p>Maltodextrin</p><p>Silica colloidal anhydrous (E551)</p><p>Sodium starch glycolate (type A)</p><p>&nbsp;</p><p><strong><em>Film-coating:</em></strong></p><p>Glycerol (E422)</p><p>Hypromellose (E464)</p><p>Macrogol 6000</p><p>Magnesium stearate (E470B)</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep the container tightly closed in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>14, 20, 28, 30 or 50 tablets in polypropylene white container equipped with a low density polyethylene flow reducer and a low density polyethylene white opaque stopper containing a white desiccant gel.</p><p>Pack sizes:&nbsp; 1 x 14, 1 x 20, 1 x 28, 1 x 30 or 1 x 50 tablets</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 x 28, 2 x 30 or 2 x 50 tablets</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 x 30 tablets</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 x 50 tablets</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Les Laboratoires Servier
 50, rue Carnot
92284 Suresnes cedex - France

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05.2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>